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Lithium carbonate, a drug for the treatment of Bipolar Disorder, provides mood stability 
to treat an illness that causes recurrent episodes of mania and/or depression.  The 
mechanism by which lithium acts to elicit these psychological changes remains unknown.  
Interestingly, this small bio-active salt has been shown to reduce the risk of suicide, and 
appears to lower the incidence of Alzheimer’s disease.  It has been proposed that lithium 
inhibits magnesium-dependent enzymes; however, there is no consensus as to how this 






P T1 and Paramagnetic Relaxation 
Enhancement (PRE) Nuclear Magnetic Resonance (NMR) methods, which can be used to 
characterize the association of lithium (Li
+
) at magnesium (Mg
2+
)-phosphorus chelation 
sites, we have identified a ATP·Mg·Li complex.   The lithium binding affinity to form 
this complex is relatively high compared to other monovalent cations, with a Kd < 1 mM, 
and biologically relevant considering that at the typical dosing of Li
+
, physiological 
concentrations of Mg and ATP are in the 0.6 – 2.5 mM range.  This has led us to propose 
a mechanism of action for lithium based on the formation of Mg·Li-complexes at 
 
 
dehydrated magnesium-phosphate sites and perhaps a role for ATP·Mg as a physiological 
carrier for Li
+
.  To test this model experimentally in the context of relevant ATP-protein 
binding sites, we have used NMR methods to characterize the formation of the complex 
at ATP binding sites on albumin.  Similarly, we initiated studies investigating the 
relevance of the ATP·Mg·Li complex to a class of purinergic receptor proteins (P2XR), 
since they are stimulated by purine agonists and have been implicated in Bipolar 
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To establish the background and significance of my thesis work, this chapter 
provides a comprehensive description of affective disorders, also called mood disorders, 
with a focus on Bipolar Disorder, and provides a history of the adoption of lithium as a 
treatment of these mental health diseases.   
 
Bipolar Disorder 
Bipolar Disorder, classically known as manic-depressive illness, is a disorder 
primarily of mood instability whereby an individual experiences intense and severe 
depression and/or mania (Table 1-1).  The majority of individuals afflicted with this 
affective disorder usually have symptoms that classify them as having either Bipolar I or 
Bipolar II Disorder.  Bipolar I and Bipolar II are delineated by the nature of the episodes 
experienced, manic or depressive, and the severity of the episode.  Primarily, Bipolar I 
patients experience manic episodes more severely, and Bipolar II patients experience 
depressive episodes more severely.  Bipolar Disorders are different from depressive 
disorders; depressive disorders include symptoms of depressive episodes that occur once, 
twice or several times throughout the life of a person without regularity [1], whereas 
Bipolar Disorders occur in a periodic fashion and are cyclical in nature. A small subset of 
Bipolar patients experience only mania or depression (unipolar), but are still classified as 
having Bipolar Disorder because of the cyclical nature of the disorder.  It has been argued 
that manic-depressive illness would be a more accurate term for the disorder because it is 
broader and allows for the emphasis on the cyclical nature of the episodes, rather than the 




Bipolar Spectrum Disorder DSM-5
a
 Definition 
Bipolar I Disorder For a diagnosis of Bipolar I Disorder, it is 
necessary to meet the criteria for a manic 
episode.  The manic episode may have 
been preceded by and may be followed by 
hypomanic or major depressive episodes. 
Bipolar II Disorder For a diagnosis of Bipolar II Disorder, it is 
necessary to meet the criteria for a current 
or past hypomanic episode and the criteria 
for a current or past major depressive 
episode.  There has never been a manic 
episode. 
 
Table 1-1.  DSM-5 criteria for the diagnosis of Bipolar I Disorder, and Bipolar II 
Disorder, two of several bipolar spectrum disorders.  Defined in the Diagnostic and 
Statistical Manual, 5
th
 Edition (DSM-5) [1].
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severe form of depression, reinforcing the sometimes misleading term, ‘Bipolar Disorder’ 
[2].  However, the current accepted term for this disorder by the American Psychiatric 
Association is ‘Bipolar Disorder’ [1]. 
  
Procedure for Diagnosis 
There is currently no blood test or brain scan that can quickly lead to the 
diagnosis of Bipolar Disorder (BD).  The process of diagnosing a person with BD begins 
with a physical examination, consultation and laboratory tests to rule out other possible 
causes for changes in mood, such as a thyroid condition, stroke, or brain tumor.  The 
patient may be referred to a psychiatrist, psychologist or other mental health professional 
once other ailments have been ruled out [3]. 
Psychiatrists use the diagnostic criteria found in the Diagnostic and Statistical 
Manual (DSM), published by the American Psychiatric Association, to gather the 
necessary information and correctly diagnose patients [1].  Important information for 
clinicians includes the type, length, and severity of emotions and other symptoms in the 
life of the patient, as well as a full family history of mental illness. The specific diagnosis 
of the spectrum of BDs may include: Bipolar I, Bipolar II, Cyclothymia, 
Substance/Medication-Induced BD, and Bipolar and Related Disorder Due to Another 
Medical Condition [1].  While the latter two disorders are self-evident, briefly, 
cyclothymic disorder is when the patient experiences several periods of hypomanic 
symptoms without a full manic episode and several periods of depressive symptoms 
without a major depressive episode within a span of two years, does not meet the criteria 
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for a psychotic disorder, and cannot attribute the symptoms to another medical condition 
or drug.  Bipolar I and Bipolar II Disorders are diagnosed according to the DSM criteria.  
For Bipolar I, a person must have at least one manic episode (Table 1-2).  For Bipolar II, 
a person must have at least one hypomanic episode and one major depressive episode 
without having a manic episode.  For the proper diagnosis of BD, the symptoms cannot 
be better explained by another disorder, such as schizoaffective disorder, schizophrenia, 
delusional disorder, or other psychotic disorder [1]. 
By way of further explaining/describing/defining the symptoms associated with 
BD, a manic episode can be distinguished from a hypomanic episode by the severity of 
the symptoms.  If there are psychotic features, or the mood disturbance is enough to 
cause impaired functioning in social or occupational settings, or hospitalization is 
required, it is a manic episode.  A hypomanic episode must present an uncharacteristic 
change in behavior and mood that is noticeable by others, but it is not severe enough to 
disrupt social or occupational functions or require hospitalization [1].  ‘Mixed features’ is 
a term that refers to a patient experiencing aspects of mania and depression within the 
same episode.  For example, patients may experience manic symptoms of irritability and 
decreased need for sleep along with depressive symptoms of anxiety, excessive guilt, and 
suicidality [4].  ‘Rapid cycling’ is when four or more episodes of mania, hypomania, 
major depression, or mixed symptoms occur within one year.  Sometimes rapid cycling 
can be so severe that multiple episodes occur within a week or even within a day [3].  
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Manic Episode Major Depressive Episode 
A distinct period of abnormally and 
persistently increased goal-directed activity or 
energy, lasting at least 1 week and present most 
of the day, nearly every day (or duration if 
hospitalization is necessary). 
 
Three (or more) of the following symptoms 
(four if the mood is only irritable) are present 
to a significant degree and represent a 
noticeable change from usual behavior: 
 
A. Inflated self-esteem or grandiosity. 
 
B. Decreased need for sleep. 
 
C. More talkative than usual or pressure 
to keep talking. 
 
D. Flight of ideas or subjective experience 
that thoughts are racing. 
 
E. Distractibility (i.e., attention too easily 
drawn to unimportant or irrelevant 
external stimuli), as reported or 
observed. 
 
F. Increase in goal-directed activity 
(either socially, at work or school, or 
sexually) or psychomotor agitation 
(i.e., purposeless non-goal-directed 
activity). 
 
The mood disturbance is sufficiently severe to 
cause marked impairment in social or 
occupational functioning or to necessitate 
hospitalization to prevent harm to self or 
others, or there are psychotic features. 
Five (or more) of the following symptoms have 
been present during the same 2-week period 
and represent a change from previous 
functioning. 
 
A. Depressed mood most of the day, 
nearly every day, as indicated by either 
subjective report or observation made 
by others. 
 
B. Markedly diminished interest or 
pleasure in all, or almost all, activities 
most of the day, nearly every day. 
 
C. Significant weight loss when not 
dieting or weight gain; or decrease or 
increase in appetite nearly every day. 
 
D. Insomnia or hypersomnia nearly every 
day. 
 
E. Psychomotor agitation or retardation 
nearly every day (observable by others; 
not merely subjective feelings of 
restlessness or being slowed down). 
 
F. Fatigue or loss of energy nearly every 
day. 
 
G. Feelings of worthlessness or excessive 
or inappropriate guilt. 
 
H. Diminished ability to think or 
concentrate, or indecisiveness. 
 
I. Recurrent thoughts of death (not just 
fear of dying), recurrent suicidal 
ideation, or a suicide attempt. 
 
The symptoms cause clinically significant 
distress or impairment in social, occupational, 
or other important areas of functioning. 
 
Table 1-2.  Diagnostic and Statistical Manual, 5
th
 edition (DSM-5) criteria for a full 
manic episode and a major depressive episode. Symptoms must not be attributable to 
another medical condition or to the effects of a substance.  Refer to the DSM-5 for more 
extensive criteria [1].  
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Prevalence and Cost to Society 
The World Health Organization collected World Mental Health surveys to assess 
disability caused by physical versus mental disorders in 15 countries.  The World Bank 
classified these countries as either high-income (Belgium, France, Germany, Italy, Japan, 
The Netherlands, New Zealand, Spain, and the USA), or middle- and low-income 
(Colombia, Lebanon, Mexico, Peoples’ Republic of China, South Africa, and Ukraine).  
The study found that in both high- and low-income countries, mental disorders were more 
disabling than physical disorders.  Mental illnesses caused more disability than physical 
illnesses in social and personal areas, whereas their impact on work and productivity was 
equal.  Also, this study found that BD was more prevalent in high-income than middle- 
and low-income countries (1.4 percent and 0.7 percent, respectively) [5]. 
In the United States of America, approximately 6.1 million, or 2.6 percent, of 
adults have BD [6].  In addition, the third most common reason for hospitalization of 
individuals between the ages of 18 and 44 is mood disorders, such as BD [7].  Bipolar 
illness affects all social classes and costs the U.S. economy billions of dollars each year 
[8]. 
Gender 
Equal numbers of men and women have Bipolar I Disorder.  However, for 
Bipolar II Disorder the data is inconclusive, as some studies show the gender ratio to be 
one while others suggest the condition is more common in females [1].  A larger 
proportion of women have symptoms of depression compared to males [9, 10].  Also, 
episodes of rapid cycling and mixed states are more likely to occur in women than in 
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men.  Men and women have different patterns of co-morbidity as well [11].  Females 
with BD are at a higher risk for alcohol use disorder than both males with BD and 




In 2012, the Centers for Disease Control (CDC) released the 2010 statistics on 
causes of death in the United States.  Suicide was the second leading cause of death in 
young people (age 15-34), with the leading cause being unintentional injury; in adults 
(age 35-44), suicide was the fourth leading cause of death.  Over all ages, suicide was the 
tenth leading cause of death [13] . 
The suicide rate in people with an affective disorder, or mood disorder, is 30 
times greater than the general population [14].  Specifically, for BD, the suicide rate is 
estimated to be 10 to 20 times higher than the general population [15, 16].  People with 
BD have a 25 – 50 percent lifetime risk of attempting suicide, and a 6 - 15 percent 
lifetime risk of completing suicide [15-19].  Some strong predictors of BD patients who 
will attempt suicide are: younger age, long periods of depression, personality disorder, 
and having attempted suicide in the past [20].  In children and adolescents with BD, 
suicide attempt has been correlated with earlier onset of illness, more severe or mixed 
episodes, comorbid disorders, physical/sexual abuse, parental depression, and family 
history of suicide [21]. 
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There are currently no FDA-approved drugs in the clinic that can be given to 
prevent suicide specifically in patients with BD.  However, lithium carbonate (Li2CO3) is 
an FDA-approved mood stabilizer for BD, and a recent meta-analysis confirmed 
additional anti-suicidal properties of lithium.  Although the analysis did not differentiate 
between unipolar and bipolar depressive disorders, the 48 randomized controlled trials 
(RCTs) including 6,674 participants showed lithium to be more effective than placebo in 
lowering the number of suicides and deaths for any reason, reducing the risk of suicide by 
more than 60 percent compared with placebo [14].  In addition, a retrospective study, 
including military veterans (who account for approximately 20 percent of suicides 
nationally [22]) with Bipolar I Disorder and Bipolar II Disorder, similarly concluded that 
patients taking lithium had a lower percentage of suicide attempts compared with those 
treated with divalproex and atypical antipsychotics [23]. 
Co-Morbidity  
Of the mental disorders that often accompany BD, anxiety disorder is the most 
common and found in 75 percent of people with BD.  Half of people with Bipolar I 
Disorder also have Attention Deficit Hyperactivity Disorder (ADHD) or a substance use 
disorder [1, 24].  People with BD are more likely to have a metabolic syndrome and 
migraines than the general population [1, 25-27].  Eating disorders, such as binge-eating 
disorder, co-occur in about 14 percent of patients with Bipolar II disorder [11].  Over half 
of individuals with Bipolar II Disorder experience three or more co-occurring mental 





While there is no current cure for BD, it can be effectively managed with 
treatment.  The most effective treatment involves open communication between the 
patient and doctor(s) and medication (i.e. lithium, carbamazepine, valproic acid) without 
abrupt changes (see subsequent section).  Patients who follow this regimen may 
experience fewer symptoms of the disorder over time.  Psychotherapy may also be 
helpful for preventing relapses of bipolar episodes [3].   
Creativity 
Despite the hardships of living with BD, one positive effect that can present with 
the disorder is increased creativity.  With the unique blend of character traits, 
temperament, and circumstances, BD may enhance creative ability, even in some cases 
while the patient is concurrently taking mood-stabilizing medication.  While the extreme 
lows of depression are traumatic, the highs of mania can be addicting, when high 
creativity, energy, elation, and thoughts flow with ease.  The fears of losing creativity or 
losing the euphoric feelings of manic episodes are major reasons for low patient 
compliance with mood-stabilizing mediation, such as lithium.  Studies have shown, 
however, that nearly 60 percent of creative people with BD who take lithium are more 
productive when treated with lithium than not.  And, 20 percent reported no change to 
their productivity.  There is an undeniable association between the creativity of some 
individuals and BD.  Although not causative or maybe even directly related, BD has had 
a role in the creative works produced by writers, artists, poets, and scientists who have 
lived with the disease.  Further research is necessary to clarify the spectrum of mania and 
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the specific impact of BD on the creativity of the individual [2].  As evidenced by the 
great number of talented and creative persons who have lived with bipolar illness, such as 
Ernest Hemingway, Virginia Woolf, Vincent Van Gogh, Richard Schumann, and Edgar 
Allen Poe, the great difficulties posed by affliction of this disease often paradoxically 
come with enormous potential for contributing to society in a unique way [28-34]. 
 
Etiology of Bipolar Disorder 
While its exact nature is unknown, the underlying cause of BD appears to be 
multifaceted.  There is strong evidence that BD is hereditary [35], however, the genetics 
of the disease are also not understood.  Children of parents with BD are 2.7 times more at 
risk for developing a mental disorder and four times more at risk for developing an 
affective disorder, such as BD, compared with children of parents with no mental illness 
[36]. 
Few clinical studies have followed the offspring of parents with BD for more than 
a decade.  One recent study reported a 12-year follow-up of 108 children of parents with 
BD.  At the initiation of the study, the offspring ranged from 12 to 21 years of age.  After 
twelve years, and at a mean age of 28, more than half of the participants developed a 
mood disorder, of which 13 percent were bipolar spectrum disorders.  The study was in 
agreement with other studies in reporting that there was a higher percentage of offspring 
with Bipolar II disorder (8 percent) than with Bipolar I disorder (3 percent).  Nearly all of 
the participants who were diagnosed with a bipolar spectrum disorder experienced a 
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depressive episode as their first affective episode.  Also, most of the participants who 
developed a mood disorder had their first episode by 25 years of age [37]. 
Genetics 
Inheritance studies, such as family, twin, and adoption studies, suggest that BD is 
hereditary [35].  The genetic linkage in families was established nearly 30 years ago and 
yet the process of pinpointing the specific genes responsible for BD only began to be 
fruitful in 2007 with the advent of Genome-Wide Association Studies (GWAS) and the 
initial publications of large sample sizes of clinical genomic data, such as those by the 
Wellcome Trust Case-control Consortium (WTCCC), and the National Institute of 
Mental Health (NIMH) [38, 39].  These and several subsequent studies discovered a 
selection of genes with genome-wide significant association, meaning genetic variation 
of these genes occurs more frequently in people with BD than the control group 
representing the non-disease general population.  The main genetic variants that were 
identified from these studies occurred in the following genes: ANK3, CACNA1C, SYNE1, 
ODZ4, and TRANK1 (Table 1-3) [40-42].  ANK3 codes for a protein, Ankyrin G, which 
serves as an anchor for neuronal potassium and sodium channels.  The protein product of 
the gene CACNA1C is a subunit of the L-type calcium channel.  The phenotypes of the 
other genes have yet to be elucidated.  These genes are now considered susceptibility 
genes in BD [43]. 
There are other genes that have been implicated in BD, but do not appear as 




Genetic Variant in Bipolar 
Disorder 
Protein Encoded by 
Gene 
Function of Protein 
ANK3 Ankyrin G 
An anchor for neuronal 
sodium and potassium 
channels 
CACNA1C 
Subunit of L-type voltage 
dependent calcium 
channel 
Respond to changes in gene 
regulation inducing neuronal 





1 out of 4 parts that form 





Cell surface protein involved 
in signaling and neuronal 
pathfinding
a
. Potential role in 
neuronal development and 
axonal myelination 
TRANK1 (unknown) 
Unknown but found to 
respond to valproic acid 
 
Table 1-3.  Genome-wide significant genetic variants and their phenotype in the BD 
population were revealed by Genome-Wide Association Studies [41-43].
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and found to be not as significant in larger cohorts.  Nonetheless, these genes are worth 
mentioning as they may also play a role in this polygenic disease.  Other implicated genes 
are: DGKH, which codes for diacylglycerol kinase [39]; ADCY2, coding for a cyclic 
AMP (cAMP) dependent G-protein coupled receptor (GPCR) involved in 
neurotransmission [43]; NCAN, coding for neurocan, a glycoprotein in the extracellular 
matrix possibly involved in cell migration and adhesion [44]; ACP1, coding for acid 
phosphatase-1, which is found to be elevated in BD patients who complete suicide [43]; 
P2RX7, coding for P2X7 purinergic ligand-gated ion channel [45-47]; and ABCA13, 
coding for an ATP-binding cassette (ABC) superfamily responsible for transport across 
the cell membrane [48]. 
The current field of BD genetics is expanding GWAS sample sizes and population 
types, mainly headed by the Psychiatric GWAS consortium (PGC) BD Working Group, 
which includes large data sets from populations around the world.  This group has also 
funded the development of a “PsychChip” for single nucleotide polymorphism (SNP) 
array analysis of DNA markers associated with psychiatric illness.  In addition, subsets of 
BD population who take lithium are being analyzed for pharmacogenetic analysis.  The 
Consortium for Lithium Genetics and Pharmacogenomics of Bipolar Disorder (PGBD) 
groups primarily spearhead understanding the genetic make-up of the population of 
lithium responders [43].   
The field of BD genomics is developing the capacity to analyze exome, which 
focuses only on the exons of the genome, and whole genome sequencing of BD patients.  
The Bipolar Sequencing Consortium consists of approximately 13 groups dedicated to 
further understanding the genetic etiology of BD through sequencing exomes and whole 
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genomes of BD patients and controls.  They have already collected ~3,500 BD and 
~5,000 control exomes.  Finally, gene-mapping studies hope to link genes with their 
function and provide key insights into the pathophysiology of BD [43]. 
 
Treatment for Bipolar Disorder 
Treatment involves a combination of different medications for patients with BD.  
The process of determining the best medicine for treatment can be difficult to navigate 
for both patients and psychiatrists, especially in the initial stages of treatment.  At first, 
treatment involves patients frequently meeting with a psychiatrist or clinical psychologist 
to closely monitor the changes in mood and to gauge the effectiveness of the drugs.  The 
goal is to find the best cocktail of drugs and dosage quantity to maximize mood stability 
and minimize side effects [3]. In the future, the ‘trial and error’ of prescribing drugs for 
mental illness may be eliminated with the advent of personalized medicine and 
establishment of a genetic basis for the efficacy of one drug over another for a particular 
individual [49].  In addition to medication, some form of therapy is often suggested for 
patients [3]. 
There are five main drugs that are prescribed for mood stabilization: lithium, 
carbemazepine, valproic acid, lamotrigine, and quetiapine (Table 1-4).  The mechanisms 
of action of all of these drugs are unknown.  In addition to the mood-stabilizing drugs, 
depending on the symptoms of the patient, antidepressants or antipsychotics may also be 
prescribed.  The effectiveness of all of these drugs varies between individuals and cases.   
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Drug Name Drug Class Indication for Use Mechanism of Action 
Lithium 
(Lithobid®) 
Mood Stabilizer  Bipolar Disorder: 
manic episodes 
 Bipolar Disorder: 
maintenance 
therapy 
Unknown; proposed to 
alter sodium transport 
in nerve and muscle 









 Bipolar I Disorder, 
manic or mixed 
episodes 
 Bipolar Disorder, 
depressive episodes 




Unknown; proposed to 
act as an antagonist at 
dopamine type 2 (D2) 








 Bipolar Disorder in 
patients over 18 
years of age: 
maintenance 
treatment of 
Bipolar I Disorder. 
Unknown; 
anticonvulsant action 












 Monotherapy and 
adjunctive therapy 
of complex partial 
seizures 
Unknown; valproate 
ion proposed to 
increase gamma-
aminobutyric acid 










Unknown; proposed to 
produce anticonvulsant 






Table 1-4.  Prescription drugs for the indication of Bipolar Disorder [50].
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Nonetheless, lithium is one of the most effective drugs for on-going mood stability in a 
person with BD. 
Lithium Treatment and Clinical Use 
The use of lithium as a drug dates back almost two centuries.  Physicians used 
lithium salts to treat everything from gout to epilepsy in the mid to late 1800s.  However, 
by the early 1900s, hopes for a cure-all tablet of lithium were dashed by the real dangers 
presented as patients experienced cardiac depression, intoxication, and death.  The 
efficacy of lithium to remedy ‘psychotic disorders’ or mood disorders, such as manic-
depressive illness, was discovered rather serendipitously by an Australian scientist, John 
Cade, in 1949, when he first noticed the lethargic effects of lithium carbonate on guinea 
pigs and his curiosity led to the case study of 10 men who were either manic (i.e., highly 
excited) or epileptic [51].  The results of this study spurred a renewed interest in lithium, 
this time in the field of psychiatry.  In particular, a Danish psychiatrist, Mogens Schou, 
spearheaded both non-blind and then ground-breaking double-blind clinical trials proving 
the efficacy of lithium treatment for both acute and prophylactic care in manic-depressive 
patients [52].  In 1970, lithium carbonate was approved by the FDA for the indication of 
manic depression in the U.S. and lithium, in the form of citrate or carbonate salts, became 
the standard drug treatment for this disorder [53].    
During the 1980s and 1990s, the quality of the clinical trials that established 
lithium as an effective mood stabilizer were criticized and questioned, especially as new 
drugs came to the marketplace.  These lithium trials were conducted when uniform 
criteria for diagnosing BD were either shifting or had not been firmly established, records 
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were not clear about reasons for patient withdrawal, and the diagnosis of depression was 
often not distinguished as unipolar or bipolar depression.  In addition, in trials where the 
same patients switched from lithium to placebo during the study, called ‘cross-over’ 
trials, the patients were abruptly, rather than gradually, removed from lithium.  It is now 
known that abrupt changes in medication, especially lithium, often result in relapses.  
Placebo patient relapses in a cross-over clinical trial could have biased the control data, 
falsely boosting the effectiveness of lithium [49]. 
Since the validity of the clinical trials was questioned, lithium use declined during 
the 1990s and the use of newer drugs, such as valproate, lamotrigine, and atypical 
antipsychotics, increased.  At the same time, the pharmaceutical industry was not 
interested in funding additional clinical trials of lithium because, as an element, lithium 
cannot be patented, and so no profit motive existed to pursue lithium as a therapy.  In 
addition, the evolution of criteria for diagnosis from a basic understanding of manic-
depression to the currently accepted full range of BDs, called ‘bipolar spectrum 
disorders’, may have made lithium appear less effective due to a wider range of patients 
with atypical symptoms who may not respond to lithium treatment [1, 49]. 
More recent clinical trials, over the last 20 years, using standardized and clearly 
delineated criteria for diagnosis have reestablished lithium as a very effective drug 
treatment.  This reestablished lithium as the gold standard comparator for new drugs.  
There is strong evidence for lithium efficacy in the treatment of acute manic episodes 
over placebo [49], although one study reported that haloperidol, an antipsychotic drug, 
was more effective than lithium in the treatment of acute manic episodes [54].  Another 
study showed that both valproate and lithium were effective treatments for mania or 
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mixed episodes over placebo [55].  It should be noted that lithium has a slow onset of 
action, approximately 6-10 days, and, therefore, it may not be ideal for treating acute 
mania.  For comparison, risperidone and olanzapine, two atypical antipsychotics, take 
effect approximately 2-6 days after treatment initiation [49]. 
Fewer clinical trials have focused on lithium efficacy in the treatment of bipolar 
depression episodes specifically.  Research shows that lithium is effective in treating 
bipolar depression, but more studies with a focus on bipolar depression or BDII 
depressive episodes may reinforce these findings.  Some clinical trials compared lithium 
to other antidepressants in the treatment of acute BDII depression, but there is not enough 
evidence to conclude that lithium is more effective than antidepressants.  In addition, few 
clinical trials have researched the effectiveness of lithium combined with other drugs, 
although initial studies have suggested certain combinations of drugs to be more effective 
than one drug alone [49]. 
Aside from acute episodes, lithium is used in preventative care.  During this 
maintenance phase, lithium is the agent of choice for BD, as it is highly effective.  
Lithium is found to be superior to placebo, carbamazepine, and valproate for maintenance 
therapy.  It is more robust in preventing mania than in preventing depression, but 
effective in both nonetheless.   Combination drug therapy for the maintenance phase has 
not been tested extensively, but some trials show superior preventative care with 





Lithium is not a perfect drug 
One aforementioned drawback to lithium treatment is the 6-10 day lag time 
between treatment initiation and therapeutic effectiveness.  Lithium intoxication is one 
danger for patients taking lithium.  Lithium levels in serum above 1.5 mM can be toxic, 
leaving a very narrow therapeutic window (0.6- 1.2 mM) [2].  Any loss of fluid (i.e., 
diarrhea, vomiting, diuretics, or volume depletion) puts the patient at risk for lithium 
intoxication.  Drug combinations, such as lithium with certain nonsteroidal anti-
inflammatory drugs (NSAIDs) or angiotensin converting enzyme (ACE) inhibitors, place 
a patient at greater risk for lithium intoxication.  Patients must be carefully monitored by 
their physician for signs of lithium intoxication, including confusion, tremors, speech, 
uncoordinated movement, uncontrollable eye movement, seizures, and impaired 
consciousness.  Lithium intoxication can lead to death so medical intervention for 
detoxification may be critical.  Lithium detoxification includes replenishing fluids with 
isotonic saline, monitoring for hypernatremia, whole bowel irrigation with polyethylene 
glycol to coat the intestines and prevent further lithium absorption, and, finally, lithium 
removal by hemodialysis [56]. 
In addition to overall toxicity, lithium can cause specific problems with kidney 
function.  Two very common side effects of lithium treatment are thirst and increased 
urine output.  Lithium causes a decreased reaction to the antidiuretic hormone (ADH) in 
the renal tubule, which can lead to nephrogenic diabetes insipidus [57].  The onset of 
nephrogenic diabetes occurs in nearly 40 percent of lithium patients [49].  Increased 
urination due to decreased ability to concentrate urine puts patients at risk for sodium 
depletion and excessive fluid loss, risk factors for lithium intoxication.  Lithium-induced 
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changes occur in the collecting tubule function [57].  Patients who take lithium for longer 
durations (in excess of 10-20 years), who are older, or who experience lithium 
intoxication episodes are at risk for two nephropathies, chronic and end-stage renal 
disease (ESRD), although they are uncommon [49]. 
Another difficulty with lithium treatment is for women who are or become 
pregnant, as lithium may have teratogenic effects on an embryo.  During the first 
trimester of development, lithium may cause Ebstein’s anomaly, a heart malformation 
[58].  However, lithium has not been firmly established as a teratogen.  A meta-analysis 
of RCTs found little evidence for congenital malformations caused by lithium treatment 
[59].  Clinically, lithium is taken with caution during a pregnancy.  A planned pregnancy 
can be carefully monitored by decreasing dosage of lithium or slowly discontinuing the 
mood stabilizer for at least the first trimester, whereas unplanned pregnancies may have 
already exposed the fetus to harm.  As mentioned earlier, abrupt discontinuation of 
lithium has been shown to cause relapse episodes, which may cause further harm to the 
fetus.  So, pregnant woman with BD must carefully weigh the decision to stop treatment, 
as untreated manic and depressive episodes put both the fetus and mother at risk [58].     
Lithium treatment is linked to several other conditions as well.  For one, 
approximately 25 percent of patients who receive lithium treatment develop thyroid or 
parathyroid maladies.  A meta-analysis of RCTs concluded that there was a higher 
prevalence of hypothyroidism in patients taking lithium compared with placebo.  The 
findings also indicated an increase in the thyroid stimulating hormone (TSH), blood 
calcium, and parathyroid hormone [59].  Lithium treatment was also associated with 
more weight gain compared to placebo [59].  Additional adverse effects of lithium 
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treatment include experiencing tremors, nausea, diarrhea, lethargy, reduced self- 
perceived creativity, and gastric discomfort [49]. 
 
Lithium benefit in neurodegenerative diseases 
Lithium is a mood-stabilizing drug and has displayed anti-suicidal benefits, but it 
has also been shown to impart neuroprotective properties.  Lithium slows disease 
progression and increases neuronal growth and protection in animal models of 
neurodegenerative diseases.  These animal models represented: stroke, Amyotrophic 
Lateral Sclerosis (ALS), Fragile X syndrome, Down syndrome, Huntington’s disease, 
Alzheimer’s disease, Parkinson’s disease, retinal degeneration, spinal cord injury, and 
human immunodeficiency virus (HIV) infection, among others [60-64].  Some of these 
findings supported the advancement to human clinical trials for lithium treatment in 
diseases such as ALS, for which there is presently no effective treatment.  Daily lithium 
doses during a 15-month observation period resulted in delayed disease progression.  
Correlation of delayed ALS in humans and an ALS mouse model points towards a 
lithium effect on increasing mitochondria in motor neurons, activated autophagy, and 
increased number of neurons [63].  Another clinical trial tested the cognitive and 
biological effects of lithium on people with amnestic mild cognitive impairment.  This 
study showed improvements such as better attention and decreased phosphorylated tau, a 
microtubule-associated protein that aggregates into neurofibrillary tangles, seen in 
Alzheimer’s disease, upon hyperphosphorylation.  These results propose lithium as a 
potential early drug intervention for the prevention of Alzheimer’s disease, which may be 
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a safer and more feasible use of lithium than in the elderly with late stage Alzheimer’s 
[65-67].  Further evidence of neuroprotective effects of lithium comes from a study of 
elderly bipolar patients who have had chronic lithium treatment compared with elderly 
bipolar patients who have not.  The prevalence of dementia in the lithium treated group 
matched the prevalence of the general population, which was significantly lower than the 
prevalence among non-lithium-treated BD elderly patients [68]. 
Lithium’s Mechanism of Action 
Although the effectiveness of lithium in treating mood disorders has been known 
for over 60 years, it is remarkable that today there is still no known mechanism of action 
for either lithium’s therapeutic efficacy or side effects.  The following research addresses 
the pharmacology of lithium as a drug treatment for BD and may serve to provide a 
guiding fundamental model for elucidating the pathophysiology of BD, the cause of 
adverse side effects of lithium ingestion and of lithium toxicity, and reasons for its 
attributed neuroprotective nature.   
The significant shortcoming of current lithium and BD research is the lack of a 
molecular mechanism of action that is supported by direct measurements under 
physiologically relevant conditions.  Previously published reports show competition of 
lithium with magnesium under non-physiological concentration ratios of lithium to 
magnesium, or otherwise lack sufficient consideration of alternate interpretations of 
complex data [69, 70].  These have been widely referenced and taken as lithium’s most 
likely physiological mechanism of action at metal binding sites, whether on enzymes, 
ATP, or ATP-bound-enzymes (see Chapter 3).   
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In an attempt to address this problem, this project sought to provide a unifying 
physiologically relevant model for how lithium works at the molecular level that could be 
tested through biochemical and biophysical experiments.  The results have led to a 








Probing Lithium’s Mechanism of Action:  
From Animal Models to Biophysical 
Approaches   
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Numerous methods have been used to try to understand how lithium acts as a 
mood stabilizer, from human clinical trials and disease models in animals to cellular 
assays.  Molecular studies of lithium, however, have been challenging and limited due to 
the small size of the element (7 Daltons) which poses challenges in experimental design 
and signal detection.  This chapter describes the different approaches that have been used 
previously to study lithium molecular and biological mechanisms, as well as those 
employed primarily in this thesis research.  The theory and practical aspects of each 
approach are outlined along with the strengths and limitations of each technique. 
 
Challenges in Lithium Research 
Animal Model Research 
Animal models have been used to mimic certain aspects of Bipolar Disorder 
(BD).  However, the subjective nature of neuropsychiatric symptoms makes modeling 
mental illnesses in animals very challenging.  Instead, animal models are used to model 
specific symptoms or aspects of the illness, rather than the entire illness in one animal.  In 
some ways, mental illness seems uniquely human.  Cognitive symptoms like 
hallucinations, delusions, sadness, and guilt cannot be easily described in a mouse model 
system.  Until the physiological basis for these symptoms is better understood, animal 
models will not be able to test these cognitive symptoms.  Instead, more measurable 
symptoms, like changes in social behavior and motivation, can be used to mimic aspects 
of mental illness in animal models.  Currently, no BD animal model exists that is capable 
of spontaneously cycling through episodes of mania and depression [71].  Therefore, 
researchers using animal models as a neurobiological tool or disease model use a range of 
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methods to simulate the disease.  Animal models of mental illness symptoms are 
generated by means of genetic, pharmacological, environmental, or electrical stimulant 
manipulations.  For example, mania is modeled in rodents that are administered 
psychostimulants, like cocaine or amphetamine.  Overexpression of glycogen synthase 
kinase-3β (GSK-3β), known to be inhibited by lithium, is also used to produce transgenic 
mice with some manic-like behaviors [72].  These mice exhibit lower ‘anxiety-like’ 
behavior in risk-taking assessments, and increased mobility and locomotion.  Another 
transgenic mania model is a loss-of-function mouse with a mutation in the Clock gene.  
These mice have altered circadian rhythms, similar to changes in sleep patterns of BD 
patients [71, 72].  There are also mouse models of depression, which are normal mice 
exposed to repeated stresses, like physical manipulations or social agitations [72]. Again, 
cognitive symptoms, such as suicidality and emotions, cannot be objectively measured, 
but changes in behavior due to stress can be similar to depression.  The rodent response 
to stress can cause changes in pleasurable activities, weight gain, and insulin levels.  
These models are validated by the reversal of symptoms by administration of 
antidepressants [72].  Taken together, these models can be somewhat useful for validating 
targets and predicting behavioral outcomes of medications [73].  However, a more 
fundamental understanding of BD is necessary to develop a more robust model of the 
disease in animals.   
 
Lithium Research in the Laboratory 
With a molecular weight of 7 Daltons, the small size of lithium poses a significant 
challenge for direct detection and purification by many commonly used biochemical 
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methods.  There is no filter or membrane small enough to trap lithium.  There is no 
radioisotope of lithium that can be used for detection, and no intrinsic fluorescence or 
fluorescent lithium-binding dye available.  In structure determination, X-ray diffraction 
cannot ‘see’ lithium ions since it is not large enough to cause a detectable signal.   
Two methods that have been used for the direct detection of lithium in biological 
research are flame Atomic Emission spectrophotometry and flame Atomic Absorption 
spectrophotometry.  Atomic Absorption or Atomic Emission are reasonable methods for 
quantifying the lithium concentration in histological slices.  Yet, only a qualitative 
assessment of the distribution and localization of lithium can be obtained by these 
methods.  In addition, the delicate process of slicing, freezing, and thawing tissue 
samples is time consuming, labor intensive and complicated.  Lithium specific 
microelectrodes were developed in the late 1970s and can detect the transport of lithium 
in living cells; however, they have not been used extensively, possibly because of the 
interference by other biological ions in the cellular milieu.  Mass spectrometry can easily 




Li isotopes.  Secondary ion mass spectrometry (SIMS) 
measures the mass to charge ratio of ions in a thin solid sample such as biological tissues 
by projecting a beam of primary ions onto the sample.  This technique is mostly 
qualitative because of the difficulty in setting standards of tissue samples, but in some 
cases quantitative measurements have been attained [74].  Nuclear magnetic resonance 
(NMR) can be used to directly detect lithium in solution in the presence of several 




Li are detectable by NMR, but 
7
Li has a much higher 
sensitivity as it is found at higher natural abundance. 
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Lithium activity in vivo has been detected by assays with secondary reporters or 
readouts.  For example, lithium inhibition of inositol monophosphatase (IMPase) was 
discovered by the buildup of the reactant, inositol monophosphate, and the decrease in 
the product, inositol, in the IMPase-catalyzed dephosphorylation reaction [75] (see 
Chapters 3 and 6 for hypotheses of lithium’s mechanism of action).  The many possible 
molecular targets of lithium can be tested at the organismal and cellular levels, but to 
elucidate the most fundamental mode of lithium action, clarity must be gained at the 
molecular level. 
 
Methods for Measuring Weak Binding 
In addition to its small size, lithium binds weakly (μM to mM) to biological 
molecules, making it difficult to measure binding and affinity of lithium for its target.  
There are a number of biophysical methods that can measure weak binding (Table 2-1).  
Isothermal Titration Calorimetry (ITC) is a thermodynamic-based method where 
endothermic and exothermic biochemical reactions are characterized by change in heat 
capacity as a function of the ligand or molecule titrated [76, 77].  In this project, lithium 
was not found to cause a detectable change in heat capacity upon binding, thus making 
this approach impractical.  Another method to measure weak binding interactions is 
equilibrium dialysis.  Equilibrium dialysis allows a system divided into two 
compartments by a partition to reach equilibrium.  A filter membrane partition between 
the two chambers is permeable to the ligand, but not to the protein.  The binding affinity 




Method Practical Limitations 
NMR 
Requires concentrated 
samples (typically near 
mM) due to low sensitivity 
Isothermal Titration 
Calorimetry (ITC) 




fluorescence or design of 
reporter 
Equilibrium Dialysis 
Requires availability of 
membrane pore size smaller 
than the ligand 
Equilibrium Gel Filtration 
Requires dynamic range of 
UV detection 
 
Table 2-1. Measurement challenges of molecules with weak binding affinity.
31 
 
calculated from the concentration of protein on one side, and the equilibrium 
concentrations of ligand in each chamber.  The concentration of the protein-ligand 
complex is calculated by obtaining the difference in equilibrium ligand concentration of 
the two chambers.  The unbound protein concentration is equal to the starting protein 
concentration minus the protein-ligand complex concentration calculated above.  This 
method requires a detectable signal to quantify the concentrations.  In theory, this method 
is simple and straightforward.  In practice, the system used in this work either did not 
reach equilibrium or did not come to equilibrium within a reasonable time frame, and the 
measured concentrations were not reproducible.   
Another method to measure binding interactions of low affinity is by Equilibrium 
Gel Filtration, which was used to measure the binding of lithium and ATP to albumin and 
is described further towards the end of this Chapter and in detail in Chapter 4 [78-80].  
 
NMR Methods for Measuring Lithium 
This doctoral research primarily employed methods in NMR spectroscopy for 
lithium detection.  Aside from Atomic Absorption, NMR is the most common method 
utilized to directly detect the lithium ion.  In addition, the natural abundance of the 
7
Li 
isotope is quite high (92.5%) so detecting the lithium NMR signal is practical in short 
time periods (minutes to hours).  NMR is well suited to measure weak binding 
interactions and to answer biochemical questions about the atomic interactions of lithium.  
The methods detailed below offer new applications of NMR for the advancement of 





NMR is a phenomenon affecting particular nuclei placed in a static magnetic field 
and exposed to electromagnetic radiation in the form of radio waves.  Nuclei that are 
observable by NMR spectroscopy have a quantum property called spin.  Spin is a 
characteristic possessed by unpaired electrons, protons, and neutrons.  Any atom with an 
odd number of protons or an odd number of neutrons has a net nuclear spin and is 
considered an NMR active nucleus.  The odd number indicates net spin property, while 
the spins of an even number of nucleons pair up and cancel each other.  
7
Li has 3 protons 
and 4 neutrons, rendering it an NMR active nucleus, directly detectable by NMR.  Nuclei 
that do not possess net spin are not detectable in NMR, but can gain a spin characteristic 
by changing the number of neutrons, as in a different isotope.  One detection limitation 
may be the natural abundance of the isotope.  
7
Li has a high natural abundance so this 
was not a limiting factor for this research (Table 2-2.). 
Nuclear spin is a constant quantum mechanical attribute of the nucleus; it never 
stops or changes speed.  The spinning positive charge creates a constant magnetic field 
that aligns with its axis of spinning.  The strength of the magnetic moment that the atom 
produces is the gyromagnetic ratio (γ), which is unique to the nuclear spin of each atom 
and does not change.  When nuclei with net spin experience an external magnetic field, 
the nuclear magnet aligns with or against the external magnet in a lower energy (α) or 
higher energy (β) state, respectively (Figure 2-1).   
The distribution of spinning nuclei aligning with and against the magnet is nearly 
equal at thermal equilibrium, but there is a slight excess of spins residing in the α state.  




NMR Nucleus Natural Abundance (%) Spin 
7
Li 92.5 3/2* 
31
P 100 1/2 
23
Na 100 3/2* 
1
H 99.985 1/2 
 
Table 2-2. Properties of NMR nuclei used in this research project.  Asterisk (*) denotes 






Figure 2-1. Energy states of an NMR-active nucleus.
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temperature.  The ratio of β spins to α spins decreases below room temperature, 
increasing the difference in the number of spins between the two states.  Conversely, the 
ratio approaches 1 at temperatures higher than room temperature, effectively decreasing 
the difference in the number of spins between the two states.  The majority of spins have 
no measurable magnetization, or signal, because for every matched spin, high and low 
energy, their emitted photons cancel each other out resulting in zero net magnetization.  
A rough estimation is that only 1 in 10
6
 spins have a detectable net magnetization upon 
absorption of a photon that can be measured.  This is the reason that NMR is an 
insensitive method and requires micrograms to milligrams of material to detect a signal.  
The NMR signal is proportional to the difference in spin population between the two 
states, or the excess of spins in one state.   
The alignment of nuclei in these two spin states is not static but rotates in a 
circular motion around the z-axis in the x-y plane as a result of the angular momentum of 
the nuclear spin and the torque exerted by the external magnetic field.  This motion, 
similar to a spinning top, is called precession (Figure 2-2).  The precession rate (ν), also 
known as the resonant frequency or Larmor frequency, is proportional to the atomic 
gyromagnetic ratio (γ), and the external magnetic field strength (B0) (Eq. 1).   
ν = γ B0 / 2π  Eq. 1 
The units of precession rate are cycles per second, or hertz.  While the 
gyromagnetic ratio is constant, the external magnetic field depends on the NMR 






Figure 2-2. Resonant frequency.
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The energy separation of spin populations by the external magnetic field is the key to 
NMR.  Like tuning a radio to a particular frequency to hear a radio station, the frequency 
of the radiofrequency pulse tunes to match the resonant frequency of the nucleus-of-
interest.  When resonance of the two frequencies occurs, those specific nuclei absorb the 
energy input and jump to the higher energy state.  Their emission of this photon can be 
detected and gives rise to a signal.  The quantum nature of these two states requires that 
the radiofrequency energy input must exactly match the energy gap in order for the 
energy of the photon to be absorbed.  This energy gap (ΔE) is related to the resonant 
frequency (ν) by Plank’s constant (h= 6.626 x 10
-34
 J s), where 
ΔE = h ν  Eq. 2 
The energy difference between the two quantum states of aligned precessing spins 
is also proportional to the field strength (B0) (Eq. 3). 
ΔE = h γ B0  Eq. 3 
A stronger, higher field magnet causes a larger gap between these two quantum 
states.  Stronger magnets are more sensitive because a higher signal-to-noise ratio can be 
achieved from a larger gap in energy states, which results in better separation between 
frequencies. 
In addition to the opposite vectors of the two spin states canceling each other out, 
the excess spins in the lower energy state have random phase at equilibrium.  While all 
the excess spins possess the same resonant frequency, the directions of the axes of these 
precessing spins are not uniform, and lack coherence.  Therefore, at equilibrium, the x 
and y components of the vector also cancel each other because all the vector directions 
are represented in the population.  The only remaining magnitude is the positive z 
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component of the spin vector.  The sum of z components results in the net magnetization 
vector, M.  The magnitude of this vector, M0, is proportional to the spin population 
difference, or number of excess spins, and the gyromagnetic ratio of the spins.  This z 
component is used in measuring relaxation detailed below. 
Coherence of the ensemble of excess spins can be achieved by applying a 
radiofrequency pulse.  The spins then precess in a uniform manner and the sum of the 
magnetization in the x-y dimensions yields a magnetization vector in the x-y dimension 
that can be detected as an NMR signal. 
The NMR signal is relayed as a measureable voltage produced by the coherent, 
precessing ensemble of spins.  The instrument that facilitates nuclei to experience the 
NMR phenomenon by providing a magnetic field is the NMR Spectrometer (Figure 2-3).  
It is a superconducting magnet produced by circulating electric current through highly 
specialized coils made of a copper alloy.  The superconducting wires operate at cryogenic 
temperatures, thus the coils are in a compartment filled with liquid helium that is 
surrounded by a secondary compartment of liquid nitrogen.  The NMR magnet has a 
specialized and removable probe that is inserted into the central bore of the magnet.  The 
probe can tune the radiofrequency input to match the resonant frequency of an NMR 
active atomic nucleus.  The NMR sample is in a 5 millimeter glass tube and rests just 
inside the top of the probe inside the magnet.  Inside the probe are shim coils that 





Figure 2-3. Nuclear Magnetic Resonance spectrometer hardware.  
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field in the x-y-z dimensions immediately surrounding the sample.  The NMR sample 
rests inside the top of the probe containing a coil that is sensitive to changes in voltage 
produced by the perturbation of the nuclei after a receiving a radiofrequency pulse. The 
voltage produced by the magnetized nuclei is a time-dependent signal called the free 
induction decay (FID) which decays over time as the nuclei return to their equilibrium 
state and coherence is lost.  The signal which is detected as a voltage is amplified and 
sent to the computer for processing and analysis. 
Taking a reductionist's approach, the research in this thesis project sought to 
resolve fundamental questions about lithium’s atomic interactions by using NMR as the 
primary method.  The results of the NMR experiments, which are described in the 
subsequent chapters, yielded a simple biophysical model that can be built upon to test in 
the more complex cellular stage.  These are the experimental methods for this research: 
 
31
P Chemical Shift Perturbation 
Chemical shift is a measurement of the change in the resonant frequency of an 
atom, characteristic of the atom’s nucleus, but also influenced by the atom’s specific 
position, or chemical environment, within a molecule; a given nucleus will experience 
slightly different magnetic fields depending on the magnetic influence of nearby nuclei, 
due either to covalent or through-space interactions.  This is why the resonant frequency 
may vary slightly from one nucleus to the next.  The chemical shift of nuclei is like a 
chemical fingerprint giving evidence of the local environment of each individual nuclei 
[81].  NMR chemical shift perturbation was measured for the phosphorus atoms of the 
phosphates of ATP in the presence and absence of lithium and magnesium ions to gain 
41 
 
information about the binding interactions of the metal ions with the phosphate groups 
(see Chapter 3).   
 
7
Li T1 Relaxation 
Nuclear spins at equilibrium have a random phase (lack coherence), as discussed 
above.  This equilibrium state is disturbed by an energy input in the form of a 
radiofrequency pulse.  The consequence of this radiofrequency pulse at the resonant 
frequency of a particular nucleus is the absorption of a photon of energy and the 
movement from the α state to the β state.  Following the absorption of energy is the 
phenomenon of relaxation.  Spin nuclei that have absorbed energy release this photon and 
'relax' back to the equilibrium spin state. 
In practical terms, relaxation gives information about molecular motion and 
binding of the atomic nuclei.  There are two types of relaxation and both occur 
simultaneously, but NMR pulse sequences can used to distinguish between the two 
modes of relaxation.  The first is T1 relaxation, also called spin-lattice or longitudinal 
relaxation, and is the type of relaxation in the z-dimension that was primarily measured in 
the research in this thesis; T1 varies depending on the quantity, proximity, and types of 
neighboring nuclear magnets [81].  The second is T2 relaxation, also called transverse or 
spin-spin relaxation.  T2 measures the loss of coherence during the return to equilibrium 
in the x-y dimensions and involves the interaction of spins with each other.  T2 is always 
faster than T1: i.e., the recovery to equilibrium in the x-y dimension is always faster than 
in the z dimension.  Atomic nuclei can relay information about the molecule to which 
they are bound by their rate of relaxation.  Although the nuclei are not themselves 
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involved in bonding, like their electrons, they experience the changes in magnetic field 
due to the nearby nuclear magnets.  The dynamics of the molecule, such as their tumbling 
in solution, or correlation time, can be inferred by rate of relaxation of the nuclei that 
receive a radiofrequency pulse. 
T1 relaxation is the time constant for the recovery of the z component of the 
nuclear spin magnetization, Mz, to return to its equilibrium magnitude, M0.  Inversion-
recovery experiments were conducted to measure the T1 relaxation of lithium nuclei 
(Figure 2-4).  In these experiments, the spins at equilibrium receive a radiofrequency 
pulse to invert them to the higher energy state.  Relaxation of the nuclei occurs for some 
time (τ).  Lastly, the remaining magnetization is observed as the nuclei relax along the z 
axis. We used 
7
Li T1 to detect whether or not lithium bound to ATP (see Chapter 3).   
Specifically, a 180˚ pulse was applied to the 
7
Li nuclear spins to invert the energy 
state of the nuclear spins.  This was followed by a recovery period where the nuclei relax 
along the z-axis.  Finally, a 90˚ pulse was applied in order to collect the z magnetization 
in the x-y dimension.  This experiment was repeated several times, varying the recovery 
time, τ, or mixing time.  The signal intensities of each experiment were plotted as a 
function of τ, and the T1 value was obtained by fitting the points to a single-exponential 
equation (Eq. 4), where I is the signal intensity. 
     (    
(    ⁄ ))  Eq. 4 
Paramagnetic Relaxation Enhancement (PRE) 
Paramagnetic Relaxation Enhancement (PRE) experiments were used to test the 
hypothesis that lithium’s mode of action is mediated molecularly through interactions 






Figure 2-4.  Schematic representation of NMR method, Inversion Recovery, to measure 
the T1 relaxation of nuclei.  T1 is time constant for the recovery of the z component of 
the nuclear spin magnetization to return to its equilibrium magnitude.  The free induction 
decay (FID) is detected over time and is Fourier transformed (FT) into the frequency 




determine whether lithium is competitive with respect to magnesium (see Chapter 3).  
This experiment employs the use of a paramagnetic atom to cause a PRE [82].  A 
paramagnetic atom has an unpaired electron.  The electron spin of the paramagnetic atom 
produces a strong magnetic field and greatly increases relaxation.  The paramagnetic 
atom will decrease T1 values of non-paramagnetic atoms within 20 - 30 Å distance of 
itself.  A decrease in T1 value is shorter time for relaxation and is therefore described as a 
relaxation enhancement that is caused by the paramagnetic atom.  The paramagnetic atom 
can serve as a probe of surrounding non-paramagnetic nuclei measured by T1 relaxation 
[81].  In the case of ionic interactions, a paramagnetic ion that is in fast exchange with 
another ion, particularly an ion that is not observable by NMR, can give insight into a 
non-observable ion by a PRE.   
Briefly, chemical exchange refers to the process in which atomic nuclei exchange 
between two or more environments.  These may be intramolecular exchanges, such as 
motion in protein side chains or conformational change in a molecule, or intermolecular 
exchanges, such as a ligand binding to a macromolecule.  Differences in certain NMR 
parameters, such as chemical shift or relaxation time, may indicate changes in the nuclear 
environment.  The NMR time-scale refers to how fast an event happens relative to the 
difference in frequency of the NMR observables, such as chemical shift or relaxation.  A 
slow exchange allows for two separate species of atomic nuclei to be observed, whereas a 
fast exchange observes the average of these two exchanges [83].   
In PRE experiments, the paramagnetic ion, manganese (Mn
2+
), was used to 
exchange with magnesium (Mg
2+
), an atom that is not directly observed by the NMR 
experiment.   Mn
2+
, while not chemically identical to Mg
2+
, has been used in studies as an 
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interchangeable reporter for Mg
2+
 sites in protein and nucleic acids [84].  Manganese was 
added in very small concentrations to the samples, with a ratio of 0.5 % Mn
2+
 to 99.5 % 
Mg
2+
.  It was verified that manganese is in fast exchange with magnesium in binding to 
the triphosphates of ATP as it rapidly sampled, on the NMR time-scale, all of the 




H) in ATP to experience a PRE.  
 
Apparent Lithium Binding Affinity 
There are two primary ways to measure the binding affinity of receptor-ligand 
interactions at equilibrium.  The first method detects the saturation of the target receptor 
as the ligand is titrated.  The second detects the association and dissociation rates of the 
ligand receptor complex as a function of ligand or receptor concentration.  We detected 
the saturation of the receptor site, ATP, by measuring the T1 relaxation of free lithium 
ligand as it shifts to bound lithium population.  Lithium is in fast exchange with ATP so 
the average of the free and bound population of lithium is represented in the data points.  
The T1 relaxation of a nucleus adopts the relaxation property of the molecule to which it 
is bound and is distinct from the T1 relaxation of an atomic nucleus not bound to the 
molecule.  As the ATP is titrated, the population of lithium nuclei shifts from the free to 
the bound state and the T1 relaxation becomes faster until it reaches saturation.  The 
binding isotherm is an inversion of a typical hyperbolic binding isotherm because the 
method of detection for binding is a reduction in the T1 relaxation.  The T1 relaxation is 
expected to be inversely proportional to the concentration of ligand bound to substrate 
and the data can be fit as follows. 
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The equilibrium dissociation constant (Kd) is defined as: 
 
   
[A][B]
[AB]
  Eq. 5 
 
where A + B  AB.  The observed 
7
Li T1 signal (Tobs) was interpreted using a two-state 
model- where the two states refer to free and ATP•Mg bound Li, and treated as the 
population-weighted average of the signals from the two states: 
                Eq. 6 
where T0 represents the free Li signal, f0 represents the fraction of free Li, Tf represents 
the ATP•Mg bound Li signal, and ff represents the fraction of ATP•Mg bound Li. 
        
(     ) 
[Li ]
  Eq. 7 
where, 
  
(   [Li ]  [ATP ])  √(   [Li ]  [ATP ])   ([Li ][ATP ])
 
 
where [Li0] is the total lithium concentration and [ATP0] is the total concentration of 
ATP. 
 
Model Tested on Cells 
Fluorescence Microscopy 
The model for the interaction of lithium with ATP in the presence of magnesium 
that developed as a result of the aforementioned experiments led to a hypothesis that 
lithium actions might be affected through modulation of the interactions of extracellular 
ATP (eATP) with cellular receptors (Chapter 3).  To test this hypothesis, in vivo 
experiments were designed and carried out.  The cellular response to ATP, or ATP in the 
presence of metals, was characterized by measuring the calcium influx facilitated by 
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ligand-gated ion channels in neuronal cells.  P2X receptors are ligand-gated ion channels 
activated by ATP, and are described in more detail in Chapters 5 and 6.  In these 
experiments, changes in calcium concentration were detected in real time using 
fluorescence microscopy (Figure 2-5).  An intracellular calcium-binding fluorescent 
reporter, Fluo-3, indicated calcium influx observed by the fluorescence emission intensity 
of Fluo-3 [85].  This experiment explored whether the presence of lithium in the 
hypothesized ATP·Mg·Li model could disrupt or modulate the normal activity of the 
P2X receptor since the ATP-activated P2X receptor regulates Ca
2+
 flow into the cell.  
 
Model Tested on Protein 
Protein Expression of P2X Receptor 
Results from the cellular studies on the modulation of the P2X receptor in 
neuronal cells (see Chapter 3) inspired the further elucidation of this effect at the isolated 
protein receptor level.  Studies were initiated to determine if lithium acts as Li-Mg-ATP 
moieties through modulation of the activity of ligand-gated ion channels such as the 
membrane purinergic receptor proteins, P2X, whose specific agonist is ATP.  These data 
were sought to provide a direct molecular linkage between the ATP-lithium model and 
the observed neuronal response (see Chapter 5 for more detailed explanation of 
experimental methods). 
 
Human Serum Albumin 
The ATP-lithium model also led to a study of a possible mechanism for lithium 





Figure 2-5. Calcium binding reporter, fluo-3, visualized by fluorescence microscopy.  
Cartoon shows the neuronal assay in four steps, detecting fluo-3 fluorescence upon ATP 
addition (A).  Expected fluorescence response at the four steps displayed in panel A (B). 
49 
 
through ATP cofactors.  Human serum albumin (HSA) was used as a model protein for 
this work (see Chapter 4).  HSA is a well-characterized blood serum protein, containing 
ATP binding site(s), which acts as a carrier of small molecules.   
HSA was chosen as a model protein because it is biologically relevant, as the 
most abundant protein found in the blood plasma, has a known ATP-binding site, and is 
generally well characterized by NMR and other methods.  It is also known as a “carrier” 
for many drugs, such as the commonly known pain medication, ibuprofen, and blood 
anti-coagulant, warfarin.  Its high solubility and stability also makes it easy to work in the 
NMR [86, 87].  In combination with the aforementioned NMR methods, the following 
experimental methods aided in the characterization of Li-Mg-ATP binding to HSA: 
 
WaterLOGSY by NMR 
Water-ligand observed via gradient spectroscopy (WaterLOGSY) is an NMR 
method that indicates the binding of a small molecule (< 750 Da) to a macromolecule 
(>30 kDa).  It is useful in drug discovery efforts to screen libraries of small molecules for 
drug targets, and in fragment-based drug discovery for the rational development of high 
affinity binding molecules.  In NMR, the small ligand has a shorter correlation time and 
diffusion rate when it is bound to the macromolecule than when it is free in solution.  If 
the ligand is not bound, it will have a longer correlation time, which will match the 
correlation time of the free ligand in solution.  The mechanics of the experiment involve 
the saturation transfer of magnetization from bulk water to the ligand via the water 





Figure 2-6. Illustration of water-ligand observed via gradient spectroscopy 
(WaterLOGSY) method for detection of ligands binding to protein (larger oval).  
Saturation transfer of bulk water and bound proton magnetization.  Bound ligands 
(circles), adopt a correlation time of larger protein, while free ligands (stars, diamonds) 
have a correlation time distinctive of free ligands. 
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binding pocket (Figure 2-6).  The ligand that binds to the macromolecule, experiencing 
the magnetization, cross-relaxes with the labile protons and water molecules bound to the 
protein.  As the ligand dissociates from the macromolecule, it carries a changed 
relaxation due to magnetization transfer from the protein bound water.  Meanwhile, more 
of the population of ligands bind and experience the cross relaxation from the protein 
bound waters, thereby increasing the detectable signal of bound ligand.  The 
intermolecular nuclear overhauser effect (NOE) from bulk water to the non-binding 
ligand would not experience the additional cross-relaxation effects of the labile protons 
and bound water on the protein and therefore exhibit a characteristic small NOE due to 
the fast molecular tumbling.   
The experiment involves taking the difference between a spectrum taken with 
water saturation and that with the saturating pulse set far away from the resonance signals 
to match any heating effects of the pulse on the sample without directly perturbing the 
actual signals.  In the difference spectrum, ligands that are bound have a negative sign 
and appear positive in the spectra, and ligands that are unbound have a positive sign and 
appear negative in the spectra [88-90].  Clearly distinguishable peaks of ligands bound 
versus unbound make this a very useful tool for determining whether a ligand is bound to 
a protein. 
 
Equilibrium Gel Filtration 
It was not possible to determine the apparent affinity of Li to ATP when bound to 
HSA by 
7
Li T1 Relaxation NMR.  The protein concentrations necessary to conduct the 
titration experiment exceeded what was practical.  Equilibrium Gel Filtration 
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chromatography was therefore used to measure the binding affinity of ATP to HSA (see 
Chapter 4).  Equilibrium Gel Filtration chromatography is a method by which a ligand-
protein binding affinity can be determined, and is particularly useful for weak binding 
affinities.  Gel filtration, or size-exclusion chromatography, separates biomolecules on 
the basis of the Stokes radius of the protein or molecules flowing through the column.  
The method of equilibrium gel filtration uses a gel filtration column that is equilibrated 
with an elution buffer containing a constant concentration of the ligand (Figure 2-7).  
When the protein is injected and eluted from the column, the ligand from the buffer binds 
to the protein.  The composition of the column resin allows large molecules to elute first, 
followed by smaller molecules.  The UV absorbance of molecules through the flow cell 
of the FPLC indicates the elution of the protein-ligand complex.  This is followed by a 
drop in UV absorbance below the baseline indicating the depletion of ligand from the 
elution buffer by the faster moving protein [80, 91-93].   
 
Applications to other Enzyme and Receptor Studies 
Measurements in the context of this biophysical model, by the methods above, 
offer new avenues for examining the enzyme inhibition of lithium in the literature and its 




Figure 2-7.  Equilibrium Gel Filtration for detecting ligand-protein complexes.  Buffer 
(blue) contains free ligand (1).  Protein (yellow) is loaded (2) and eluted (3) from the 
column with protein-ligand complex.  Lower concentration of free ligand (light blue) is 







A General Molecular Model for 






Lithium has been used in ‘treatments’ of various ailments since the 1850s, was 
repurposed to treat ‘psychotic excitement’ by Australian scientist, John Cade, in 1949, 
and was officially approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of Bipolar Disorder(BD) (manic-depressive illness) in 1970.  Today, despite 
advances in modern medicine and drug development, lithium is still prescribed as the 
standard treatment for mitigating and preventing damaging/detrimental mood swings.  
Aside from a small subset of patients with BD, most patients find this treatment to be 
extremely effective, despite the negative side effects and other downsides.  Despite over 
60 years of lithium research, the mechanism of action of lithium therapy remains 
unknown. 
 
Biochemical Mechanism of Action- Original Focus on Magnesium 
 
At first pass, it seems unlikely that lithium carbonate would cause any noticeable 
effect on a person.  Despite its small 7 Dalton size, lithium (Li
+
) salts have an outsized 
effect on mood stability in people with BD.  Li
+
  provides a treatment for many patients 
through prophylaxis of mood swings, stabilization of acute manic episodes and lower 
incidences of suicide where other drugs have failed [52].  Magnesium (Mg
2+
), a Group 
2A alkaline earth metal, has a diagonal relationship with Li
+
  on the periodic table, 





  are quite close to each other at 0.60 Å and 0.65 Å, respectively, and to other 
neighboring atoms on the periodic table [95].  Li
+
 and calcium (Ca
2+
) also have similar 
chemical characteristics such as their hydrated radii, electronegativity, and polarizability 




  ions are more strongly hydrated than the other ions of 
56 
their respective groups [96]. Mg
2+
  is hexahydrated, coordinating with 6 water molecules 
when it is not bound by other ligands, and Li
+
 is tetrahydrated, organizing 4 water 




 are intricately involved in 
numerous biological processes, the introduction of exogenous lithium into humans may 









Historical Perspective for Current Theory of Lithium’s Mechanism of Action 
Hypotheses for the molecular mechanism of lithium’s action were first proposed 
in the years after the FDA approved lithium carbonate as a drug for manic episodes in 
1970.  In a brief exposé in 1976, inorganic chemists Dr. J.J.R. Frausto Da Silva and R.J. 










thereby cause a biological effect [99].  The diagonal relationship between lithium and 
magnesium developed into a theory of lithium substituting for magnesium in vivo due to 
their physical similarities.   Da Silva and Williams stressed the importance of considering 
the experimental conditions, e.g., media in which the measured reaction takes place, and 
emphasized that an absolute stability (affinity) constant may be misleading in a biological 
system.  Rather, they reported ‘conditional’ stability constants using adenosine 5'-
triphosphate (ATP) as a sequestering agent for divalent cations, and then in the same 
mixture measured stability of the cations bound to a uric acid derivative.  They reported 
that in favorable conditions, lithium could “compete with magnesium to some 20-30 
percent for its binding sites.” Based on the chemical structure of this uric acid derivative, 
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Da Silva showed that lithium preferred chelating sites and this lead him to propose that 
lithium challenged magnesium in key enzymes [100].  This elicited a response from 
lithium pharmacologist Nicholas J. Birch, who in 1975 published gel filtration data that 
probed lithium and nucleotide interactions.  Birch presented a revised interpretation of 
DaSilva’s data that pointed out that Da Silvia did not consider that lithium may bind to 
the ATP as well.  Birch even speculated on the possibility of lithium binding in a 
complex with nucleotide and magnesium [101].  He proposed that lithium may actually 
have its therapeutic effect by interrupting ATP-ADP equilibria in key enzymes such as 
ATPases.  Of special note was the statement in the report that they had “concluded that 




-ADP type though 
this awaits confirmation by physical methods [102].”   
Although there is no consensus in the literature on hypotheses for the mechanism 









C (carbon), and 
31
P 
(phosphorus) Nuclear Magnetic Resonance (NMR) chemical shift perturbations of ATP, 
which give information about the chemical environment of the selected nuclei, and 
7
Li T1 
relaxation times, which can offer information about binding events, ATP and ADP have 




 could occur.  As such, 
this early NMR data did not support Birch’s proposed ternary nucleotide complex.  In 
many of these 
31
P NMR studies, however, the lithium concentration was two orders of 
magnitude higher than Mg
2+
 (e.g., 300:1) because of its lower affinity for ATP or ADP 
than Mg
2+
, and also to observe a significant chemical shift [69].  The observed 
31
P 






; however, the result of using such a high lithium concentration (150 mM LiCl) 
relative to magnesium more than likely represents a non-physiological ‘salting’ effect, 
and so the interpretation of these results in the context of the in vivo mechanism of 
lithium action must be carefully considered.  Despite the fact that the conclusions from 
these studies are misleading, competition of Li
+
 at lower affinity Mg
2+
 sites in vivo is the 
most widely presumed underlying chemical mechanism of action reported in the 





, and ATP.  In a slow exchange regime at low temperatures, it is possible 
to see signals for the free and bound positions of ATP.  Using 
31
P chemical shift 
perturbation, it was shown that Li
+
 preferentially displaced Na
+
 rather than Mg
2+
, in the 
ATP∙Na versus the ATP∙Mg metal complexes.  The authors, however, did not discount 




 in biological systems given the most favorable 
conditions [103].   
Results and Discussion  
To test whether Li
+
 binds in a competitive manner with respect to Mg
2+
, we used 
a simplified model of Mg
2+
 binding to ATP (Figure 3-1), whose beta (β) and gamma (γ) 
phosphates are chelated by Mg
2+
 with an affinity of roughly 100 μM [104].  To determine 
a saturating amount of Mg
2+
 that was also stoichiometric with ATP, phosphorus chemical 
shift was measured at increasing Mg
2+
 concentrations (Figure 3-2).  Each phosphate peak 
in the presence of Mg
2+
 represents an averaging of the free and bound states because 
Mg
2+
 is in fast exchange with ATP.  The titration of Mg
2+
 into a sample of ATP caused a 
chemical shift, particularly in the β and γ phosphates where Mg
2+




Figure 3-1.  Line-angle formula of Adenosine 5’-Triphosphate (ATP) with Mg
2+
 bound 




Figure 3-2. 1D 
31
P of magnesium titrated in to a sample of 10 mM ATP.  The α, β, and γ 
phosphates of ATP are labeled in the top NMR spectrum and shift slightly with the 
addition of MgCl2.  The total MgCl2 concentration is indicated at the left of each 
spectrum. Data collected on 600 MHz NMR Spectrometer at 310 K.
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Additionally, significant line broadening is evident in the intermediate exchange 
regime, where the free phosphate population is shifting to Mg
2+
-bound.  Saturation of the 
ATP phosphates by Mg
2+
 is shown by the shifted peak sharpening, or having a more 
narrow line width, with increasing concentration of Mg
2+
, representing a shift in the 
average population of phosphorus to the fully bound state.  At 11 mM MgCl2 
concentration, the 10 mM ATP was fully saturated as seen in the bottom spectra of Figure 
3-2.  The influence of Li
+
 on a fully saturated Mg
2+
-binding site, ATP, was initially 
assessed by 
31
P 1D NMR under stoichiometric conditions of Li
+
 (10 mM added) (Figure 
3-3).  The top two 
31
P spectra represent the ATP free (purple) and ATP∙Mg bound 
(green).  The addition of 10 mM LiCl (red) does not cause an appreciable change in 
chemical shift for any of the phosphorus nuclei.  This spectrum therefore does not show 
any evidence that Li
+
 competes with Mg
2+
 for binding to ATP, but also does not provide 
an indication of any Li
+
 binding to ATP·Mg.  The bottom spectrum (blue) shows a very 
slight chemical shift in the phosphates of ATP due to Li
+
 alone, showing that in this 
instance the binding of Li
+
 to ATP can be detected through chemical shift perturbation.  
Using lithium (
7
Li) as the nucleus for detection, we measured the binding behavior of 
lithium by observation of the 
7
Li T1 relaxation, a nuclear spin phenomenon that is 
measurable by NMR through an inversion recovery experiment using a radiofrequency 
pulse in the context of an external magnetic field.  Unlike many methods which detect 
secondary effects upon lithium addition, NMR spectroscopy is able to directly detect 
lithium, and is able to distinguish between the free and bound states of lithium.  As Li 
binds to a larger substrate and the population shifts from ‘free’ ion to bound, the 




Figure 3-3. 1D 
31
P Chemical shift perturbation of the phosphates of ATP with the 
addition of MgCl2 and LiCl.  The α, β, and γ phosphates of ATP are labeled in the top 
NMR spectrum.  The sample composition is indicated at the right of each spectrum. Data 




Li T1 relaxation data (open circles) displays a plot of the peak 
intensities as a function of relaxation delay (D1) in seconds (Figure 3-4).  These points 
are fit to a single exponential yielding an overall T1 relaxation time constant.  The 
7
Li T1 
relaxation for 10 mM LiCl and 11mM MgCl2 in the absence of ATP was determined to 
be 12.8 s at 283 K (10°C), as a measure of the unbound free Li
+
 ion in solution (Table 3-
1).  The 
7
Li T1 relaxation of 10 mM LiCl in the presence of 10 mM ATP and 11mM 
MgCl2 was determined to be 6.7 s, which is about two-fold faster than the T1 of Li
+
 free 
in solution, signifying that Li
+
 is binding ATP in a measureable way. 
Unlike the 
31
P chemical shift, which is insensitive to lithium binding, the 
7
Li T1 
relaxation clearly indicates that Li
+
 binds to ATP in the presence of Mg
2+
, but this 
measurement alone does not provide information about the location and/or possible 




 binding.   To address these questions, we employed 
the use of a paramagnetic nucleus, manganese (Mn
2+
), to detect whether Li
+
 is displacing 
the Mg
2+
 from ATP prior to binding.  The electron magnetic dipole moment of Mn
2+
 
causes a relaxation enhancement to all nuclei within an approximate distance of 30 Å.  
The paramagnetic relaxation enhancement (PRE), effectively an increase in nuclear T1 
relaxation (i.e. a shorter correlation time) is measurable by NMR inversion recovery 




 of 1: 220 was used and, due to the fast 
exchange at the Mg
2+




 rapidly samples all available Mg
2+
 binding 
sites on ATP in the sample giving insight into the local environment of Mg
2+
.  Fast 














Figure 3-4.  Representative 
7
Li T1 relaxation data in the absence of MnCl2 (open circles) 
and presence of 50 μM MnCl2 (closed circles).  Line fits to a simple exponential are 
shown.  
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NMR Experiments on 600 MHz NMR Spectrometer at 283 K 
ATP Mg Li 
7
Li T1 (s) 
7
Li T1 (s) 
(+ 50 μM Mn) 
Relaxation 
Enhancement (%) 
- + + 12.80 12.10 5.5 
+ + + 6.70 2.62 60.9 
 23Na T1 (ms) 
23
Na T1 (ms) 
(+ 50 μM Mn) 
Relaxation 
Enhancement (%) 
+ + + 34.2 34.0 0.6 
10 mM 11 mM 10 mM  
 
Table 3-1.  
7
Li T1 relaxation time constants are given for 11 mM MgCl2 and 10 mM LiCl 
in solution and with the addition of 50 μM MnCl2.  
7
Li T1 relaxation time constants are 
given for 10 mM ATP, 11 mM MgCl2, 10 mM LiCl in solution and with the addition of 
50 μM MnCl2.  
23
Na T1 relaxation time constants are given in the presence and absence 
of 50 μM MnCl2.  Relaxation Enhancement (%) was calculated by subtracting the PRE (+ 
MnCl2) T1 value from the initial T1, dividing the difference by the initial T1, and 
multiplying by 100.  Experiments collected on a 600 MHz NMR spectrometer at 283 K. 
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(blue) of 50 μM MnCl2 (Figure 3-5).  Non-uniform broadening is observed due to the 
distance dependence of the Mn
2+
 electron magnetic moment.  For example, the H8 is 
broader than the H2 proton due its closer proximity to the Mn
2+
 and also indicates the 
adenosine and phosphate tail of ATP are in the ‘anti’ conformation. 
PRE on 
7
Li T1 was used to probe Li
+
 binding to ATP∙Mg.  There are three 
theoretical outcomes of adding a stoichiometric amount of Li
+
 to ATP∙Mg:  Li
+
 could 1) 
not bind to ATP∙Mg, 2) bind to ATP by displacing the Mg
2+
, or 3) bind to ATP∙Mg 
without displacing the Mg
2+
 (Figure 3-6). Through direct detection of the Li
+
 by NMR, a 
7
Li T1 PRE would indicate that the sites being sampled by Mn
2+
 are located in proximity 
(< 30 Å) to the Li
+
.  Conversely, a 
7
Li T1 PRE would not be observed if Mg
2+
, or its 
paramagnetic sampler, is displaced by Li
+
.  Additionally, no PRE would be observed if 
Li
+
 does not bind to ATP∙Mg.  Representative 
7
Li T1 relaxation data, mentioned earlier, 
showing the plot of 
7
Li peak intensities as a function of relaxation delay clearly shows a 
PRE of the 
7
Li T1 relaxation with the addition of 50 μM MnCl2 (closed circles) to the 
sample of 10 mM ATP, 11 mM MgCl2, and 10 mM LiCl compared to the sample without 
Mn
2+
 (open circles) (Figure 3-4).  The PRE experiment resulted in a T1 relaxation 
enhancement from 6.70 seconds to 2.62 seconds (Table 3-1).  This finding is direct 
evidence that under stoichiometric conditions, Li
+
 does not displace the Mg
2+
 on ATP, 
but rather binds within 30 Å to the Mg
2+
 on ATP∙Mg.   
As a control, the addition of Mn
2+




 alone in buffer 
yielded a 
7





the absence of Mn
2+
, 12.8 ms.  No PRE was observed in this control, lending confidence 







P NMR Spectra of ATP with (bottom) and without (top) 50 μM MnCl2 (left).  
1
H NMR Spectra of ATP with (bottom) 






Figure 3-6.  Possible binding modes of lithium are illustrated with ATP phosphates (red 
spheres), Mg
2+








 in solution.  Rather, the observation of PRE indicates that Mg
2+
 is present 
upon Li
+
 binding to ATP.  Furthermore, since all samples contain sodium (Na) in the 
buffer solution, we measured the 
23
Na T1 relaxation for a sample containing ATP, 
MgCl2, and LiCl and found it to be 34.2 ms in the absence of Mn
2+





 has no significant PRE in the presence of the paramagnetic ion at 
these concentrations.  However, Na
+
 has a larger quadrupole than Li and relaxes an order 
of magnitude faster.  Although this is not a perfect control, the Na
+
 concentration is 5 
times higher than the concentration of Li
+
 in the sample and a PRE is still not observed.  
This may be an indication that Na
+
 does not bind appreciably to ATP∙Mg. 
The observation of Li
+
 binding to ATP∙Mg led to the question of whether other 
nucleotides exhibited a similar Li
+
 binding behavior.  
7
Li T1 relaxation PRE experiments 
were collected with nucleoside di- and tri- phosphates (Table 3-2).  Guanosine 5’-
triphosphate (GTP), adenosine 5’-diphosphate (ADP) and guanosine 5’-diphosphate 
(GDP), whose phosphates are known to chelate Mg
2+
 with varying affinities [105, 106], 
were all observed to interact with lithium in the presence of Mg
2+
 and each exhibited a 
PRE when the 
7
Li T1 relaxation was measured in the presence of Mn
2+
.  This again 
shows that Li
+
 is binding in proximity to Mg
2+
.  ADP and GDP exhibit a relaxation 
enhancement of 77 percent and 55 percent, respectively, which is in the range of ATP at 
61 percent, while GTP appears to have slightly smaller enhancement of 26 percent.  One 
could speculate that the amino group at position 2 of GTP may interact with the 
triphosphate tail and destabilize Li
+
 binding leading to the observed variation in T1.  
Similar to the 
23
Na T1 control experiments for ATP discussed above, a PRE of the 
23
Na 
T1 relaxation is not observed with Mn
2+
 addition and serves as an internal control for the   
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NMR Experiments on 600 MHz NMR Spectrometer at 283 K 
ADP Mg Li Mn 
7
Li T1 (s) 
23
Na T1 (ms) 
+ + + - 5.94 31.4 
+ + + + 1.36 36.4 
10 mM 11 mM 10 mM 50 μM   
Relaxation Enhancement (%): 77.1 -15.9 
    
  
GTP Mg Li Mn 
7
Li T1 (s) 
23
Na T1 (ms) 
+ + + - 5.98 31.3 
+ + + + 4.44 37.10 
10 mM 11 mM 10 mM 50 μM   
Relaxation Enhancement (%): 25.8 -18.5 
    
  
GDP Mg Li Mn 
7
Li T1 (s) 
23
Na T1 (ms) 
+ + + - 9.47 36.9 
+ + + + 4.23 36.6 
10 mM 11 mM 10 mM 50 μM   
Relaxation Enhancement (%): 55.3 0.8 
 
Table 3-2.  
7
Li T1 relaxation and PRE compared to control of 
23
Na T1 relaxation and no 
PRE observed for ADP, GTP, and GDP.  Relaxation Enhancement (%) was calculated by 
subtracting the PRE (+ MnCl2) T1 value from the initial T1, dividing the difference by 
the initial T1, and multiplying by 100.  Experiments were collected on a 600 MHz 
spectrometer at 283 K.
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ADP, GTP, and GDP measurements.  In fact, a negative percentage for relaxation 
enhancement was observed for ADP and GTP, indicating that the T1 relaxation slowed 
with the addition of Mn
2+
, although it is not clear why this would occur.  The 
7
Li T1 
relaxation data provides clear evidence that Li
+
 binds to ATP∙Mg, ADP∙Mg, GDP∙Mg, 
and GTP∙Mg under stoichiometric binding conditions.   
The next consideration is whether the nucleoside base and ribose sugar are 
necessary for Li
+
 binding close to the Mg
2+
 site.  
7
Li T1 experiments were applied to test 
Li
+
 binding to triphosphate∙Mg.  The
 7
Li T1 of a sample of 10 mM triphosphate, 11 mM 
MgCl2, and 10 mM LiCl measured 1.39 seconds.  This T1, which is faster than the free 
Li
+
 ion, indicates that Li
+
 is bound to the triphosphate.  Apparently, Li
+
 binding does not 
require the nucleoside base and ribose sugar moiety nor does it displace the Mg
2+
 ion, as 
observed through 
31
P chemical shifts (data not shown). 
This finding led to the question of whether other molecules with phosphates 
would bind to Li
+
 in a similar way.  2,3-diphosphoglycerate (DPG), also known as 2,3-
bisphosphosglycerate, a small molecule found in erythrocytes, is known to chelate Mg
2+
 
(Figure 3-7) [107-109].  Initial 
7
Li T1 PRE measurements were collected on a 500 MHz 
NMR (Table 3-3) and later repeated on a 600 MHz NMR (Table 3-4).  At both the lower 
and higher magnetic field strengths, the results were expected to show the same trends.  
Indeed, a 
7
Li PRE is observed in the presence of Mn
2+
 at both the higher and lower field 
strengths, and relaxation enhancements were approximately 60 percent.  Again, 
23
Na T1 
control experiments did not show a PRE, indicating, to some degree, that Na
+
 does not 
bind appreciably with Mg
2+
 to DPG in the presence of Li
+









Figure 3-7.  Line-angle formula of 2,3-diphosphoglycerate (DPG) (top) and 




Li T1 Relaxation Experiments on 500 MHz NMR at 283 K 
DPG Mg Li Mn 
7
Li T1 Relaxation (s) 
+ + + - 7.65 
+ + + + 2.92 
10 mM 11 mM 10 mM 50 μM  
Relaxation Enhancement (%) 61.8 
     
23
Na T1 Relaxation Experiments on 500 MHz NMR at 283 K 
DPG Mg Li Mn 
23
Na T1 Relaxation (ms) 
+ - - - 16.02 
+ - + - 17.17 
+ + - - 27.10 
+ + + - 27.24 
+ + + + 27.39 
10 mM 11 mM 10 mM 50 μM  
Relaxation Enhancement (%) -0.6 
 
 
Table 3-3.  
7
Li T1 relaxation experiments showing lithium binding to 2, 3- 
diphosphoglycerate (DPG) and the 
23
Na T1 relaxation controls showing sodium.  
Relaxation Enhancement (%) was calculated by subtracting the PRE (+ MnCl2) T1 value 
from the initial T1, dividing the difference by the initial T1, and multiplying by 100.  
Experiments collected on a 500 MHz NMR spectrometer.
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DPG Experiments at Different Temperatures - 600 MHz NMR 
    7Li T1 Relaxation (s) 
DPG Mg Li Mn 283K 298K 310K 
+ + + - 6.86 8.27 10.18 
+ + + + 2.79 3.40 3.84 
10 mM 11 mM 10 mM 50 μM    




Li T1 relaxation data of lithium binding to DPG in the presence of 
magnesium at 283 K, 298 K, and 310 K.  Relaxation Enhancement (%) was calculated by 
subtracting the PRE (+ MnCl2) T1 value from the initial T1, dividing the difference by 
the initial T1, and multiplying by 100.  Experiments collected on a 600 MHz NMR 
spectrometer.
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binding at phosphate∙Mg sites as this is a common feature between the nucleotides, 
triphosphates, and DPG. 
Ethylenediaminetetraacetic Acid (EDTA) is known to chelate magnesium with its 
coordinating carboxyl groups (Figure 3-7) [110].  To determine if Li
+
 specifically 




Li T1 relaxation PRE experiments were 
measured on EDTA∙Mg (Table 3-5).  The 
7
Li T1 is 22.58 seconds in the absence of Mn
2+
, 
and 10.41 seconds in the presence of Mn
2+
, indicating a PRE.  The relaxation 
enhancement of 53.9 percent indicates that it is possible for Li
+
 to bind to Mg-chelation 
sites comprised of coordination ligands other than phosphates.  This suggests that, in 
addition to nucleotides and other phosphate-containing small molecules, there may be a 
role for Li
+
 to act together with Mg
2+
 at Mg-sites on proteins, although that remains to be 
tested. 
Returning to the nucleotide model for Mg
2+
 binding, and having established that 
Li
+
 binds to ATP∙Mg without displacing the Mg
2+
, NMR was used to quantify the Li
+
 
affinity for ATP∙Mg by direct detection of 
7
Li.  The 
7
Li T1 relaxation was observed at 2 
mM LiCl as a function of increasing ATP∙Mg concentration.  Non-linear least squares 
fitting to a quadratic function for the observed 
7
Li T1 relaxation at different 
concentrations of ATP∙Mg gave information about the binding affinity of Li
+
 (see 
Chapter 2) (Figure 3-8).  The plot shows the initial T1 relaxation of Li
+
 in the absence of 
ATP∙Mg (0 mM).  As aliquots of ATP∙Mg were titrated into a LiCl sample, faster 
relaxation was detected and over the course of the titration the T1 time constants capture 
the transition from free Li
+
 (0 mM ATP∙Mg) to fully bound ATP∙Mg∙Li.  The change in 
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EDTA Experiments at 600 MHz 
    7Li T1 
Relaxation (s) 
EDTA Mg Li Mn 310 K 
+ + + - 22.58 
+ + + + 10.41 
10 mM 11 mM 10 mM 50 μM  





Li T1 relaxation data of Li
+
 binding to EDTA in the presence of Mg.   
Relaxation Enhancement (%) was calculated by subtracting the PRE (+ MnCl2) T1 value 
from the initial T1, dividing the difference by the initial T1, and multiplying by 100.  





Figure 3-8. A plot of 
7
Li T1 relaxation (black circles) at 283 K measured using 18 
samples as a function of increasing concentrations of ATP and MgCl2 and a constant 
concentration of 2 mM LiCl.  Data was fit using equation 7 (Chapter 2) to yield a KD of 
1.52 mM.  Data collected on 600 MHz NMR Spectrometer.  
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relaxation is directly correlated to the proportion of Li
+
 bound to the ATP∙Mg substrate at 
a given data point.  The equilibrium dissociation constant (KD) of Li
+
 for ATP∙Mg, which 
was measured in triplicate at 283 K, was found to be 1.52 with a standard deviation of ± 
0.11 mM.  Due to the nature of the long T1 experiments and the large number of samples, 
the ATP in each sample was checked by 1D 
31
P NMR for degradation (Figure 3-9).  Of 
the 17 samples, only 1, the sample with the lowest concentration of ATP·Mg (bottom 
spectra) showed any hydrolysis of ATP at the completion of the 
7
Li T1 experiments.  
Overall, the integrity of ATP was confirmed in the samples, as ADP phosphate peaks 
would have otherwise appeared between the α and γ phosphate peaks of ATP. 
The weak, but appreciable, binding of Li
+
 to ATP∙Mg raised the question as to the 
minimally required molecules for the lithium binding event to occur.  The PRE data 
verified that Li
+
 binds to Mg
2+
 sites on other nucleotides and small molecules.  Variation 
in Li
+
 affinity measurements may give clues as to a preferred Li
+
 binding environment.  
Similar to the ATP∙Mg titration, ADP∙Mg, GTP∙Mg, and GDP∙Mg were titrated into 2 
mM LiCl in separate experiments (Table 3-6).  All the molecular entities tested exhibit 
Li
+
 binding with equilibrium dissociation constants in the low millimolar range.   The KD 
of Li
+
 to ADP∙Mg is 3.24 mM with an uncertainty of ± 0.56 mM, for GTP∙Mg is 4.81 
mM with an uncertainty of ± 0.55 mM, and for GDP∙Mg is 6.76 mM with an uncertainty 
of ± 1.21 mM.  The results show that Li binds with relatively similar affinity, i.e., within 
~1.5-2-fold, regardless of whether there are two or three phosphates on the nucleotide, or 
which purine base, adenine or guanine, is present.  The Li
+
 affinity to the 
triphosphate∙Mg was also determined in a similar manner.  At 283 K, the Li affinity to 
triphosphate∙Mg was 0.71 mM with an uncertainty of ± 0.23 mM and at 310 K, it was   
79 
 
Figure 3-9. 1D 
31
P of ATP in 17 NMR samples used to measure Li
+
 binding affinity.  The α, β, and γ phosphates of ATP are labeled 
in the top spectrum.  The ATP·Mg concentration increases from the bottom to top spectrum.  Collected on 600 MHz NMR at 283 K.
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0.31 mM with an uncertainty of ± 0.16 mM.  The KD of Li
+
 to triphosphate·Mg may be 
lower than that of Li
+
 to nucleotide·Mg because the triphosphate is unrestrained by the 
nucleoside and has one extra negative charge on a terminal phosphate, which may 
increase the propensity for Mg
2+
 binding while still only binding to one Mg
2+
 ion at a 
time.  The Li
+
 may have a higher rate of association with triphosphate·Mg as a reflection 
of higher on rates of Mg
2+
 to triphosphate.  This may be the reason for a lower 
dissociation constant.  Taken together, this data indicates that, minimally, Li
+
 associates 
with molecular entities other than ATP and suggests that the minimal requirement for 
binding is phosphate·Mg.  However, the equilibrium dissociation constant of Li
+
 to 
EDTA∙Mg is 6.01 mM with an uncertainty of ± 2.72 mM, which is also in a similar 
binding range to the nucleotides and adds another possibility of Li binding at 
carboxylate·Mg
2+
 chelation sites (Table 3-6).  The Li affinities measured for the 
nucleotides are physiologically relevant findings because they are on the order of 
magnitude with the serum concentration safely allowed for patients with BD (0.6-1.2 
mM). 
The PRE and binding affinity evidence for Li
+
 binding to EDTA·Mg indicates 
that carboxylate·Mg·Li may be an alternate way for Li
+
 to interact and other 
combinations may exist.  However, the full range of biologically relevant Mg chelation 
sites that can form a Li
+
 complex to explain the mechanism of Li
+
 action was beyond the 
scope of this dissertation.  The ATP∙Mg∙Li molecular entity was chosen as the focus for 
this dissertation as a possible mode for Li
+
’s interaction in a biological context, and the 
PRE and binding affinity evidence led to the hypothesis that the pharmacological 
mechanism of action of Li
+
 may involve modulation of normal ATP interactions, such as  
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Molecule Temperature (K) Lithium KD (mM) 
ADP·Mg 283 3.24 ± 0.56 
GTP·Mg 283 4.81 ± 0.55 
GDP·Mg 283 6.76 ± 1.21 
DPG·Mg 
283 0.89 ± 0.13 
310 0.71 ± 0.11 
EDTA·Mg 310 6.01 ± 2.72 
 
Table 3-6.  Lithium equilibrium dissociation constants for ADP•Mg, GTP•Mg, 
GDP•Mg, DPG•Mg, and EDTA•Mg.  The dissociation constant (KD) was calculated from 
7
Li T1 relaxation NMR measurements.  Experiments were collected on two different 600 
MHz NMR spectrometers.
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those that occur in ATP-dependent enzymes and ATP-activated receptors.  One example 
of ATP activated receptors are purinergic, or P2, receptors (see Chapter 5).  There are 
two classes of ATP-activated P2 receptors, P2X and P2Y, which are responsible for 
calcium (Ca
2+
) regulation, among other functions, and can be found in the cell membrane 
of many neurons, among other cells.  P2X receptors are ion channels that regulate 
calcium uptake by the cell and P2Y receptors are G-protein coupled receptors that 
regulate intracellular Ca
2+
 concentrations through signaling cascades (see Chapter 5).   
Fluorescence microscopy experiments were employed by our collaborator, Dr. 
Joseph Kao at the University of Maryland School of Medicine, to measure the neuronal 
response upon stimulation with ATP∙Mg∙Li.  Nodose ganglion neurons, which express P2 
receptors [85], were prepared by enzymatic dissociation of ganglia dissected from rats.  
The concentration of Ca
2+
 increase from basal level was measured upon activation of the 
P2 receptors a function of time using a Ca
2+
 binding fluorescent dye, Fluo-3, on a Laser 
Scanning Confocal Microscope.  Initially, control experiments measured the variability of 
P2 response to repeated ATP stimuli within a single neuron (Figure 3-10).  The paired t-
test between the first and third application of ATP indicated that repeated responses in the 
same cell are not significantly different.  After establishing that, the neuronal response to 
ATP∙Mg was measured and compared to the response of ATP with no metals, and then to 
ATP∙Li with no Mg
2+
 (Figure 3-11).  The P2 receptors appear to be stimulated to a 
similar extent indicated by similar peak intensities, but the addition of ATP∙Li into the 
extracellular buffer increases the length of time that P2X remains open compared to both 
ATP alone and ATP∙Mg, by 39 percent.  The addition of Li
+
 to ATP in the absence of Mg 




Figure 3-10.  Fluorescence response after 4 separate 20-second applications of 100 μM 
ATP.  Fluorescent calcium indicator is Fluo-3.  Experiments were collected on a laser 
scanning confocal microscope. The paired t-test indicates that repeated responses in the 




 response: n=9; <t100-20> = 
114, 112 sec, σ = 121, 121 sec; p= 0.83).  Data was provided by Dr. Joseph Kao, 




Figure 3-11.  Fluorescence response after 4 separate 20-second applications of 100 μM 
ATP·Mg (first and fourth application), 100 μM ATP (second application), or 100 μM 
ATP·Li (third application).  Fluorescent calcium indicator is Fluo-3.  Experiments were 










 response (ATP vs. ATP·Li, [Mg
2+
]0= 0 mM) n=12; <t100-20> = 139, 193 sec, σ = 
102, 138 sec; p = 0.015).  Data was provided by Dr. Joseph Kao, University of Maryland 
School of Medicine. 
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receptors by ATP∙Mg was compared to ATP∙Mg∙Li (Figure 3-12).  Again, the relative 
fluorescence intensities were approximately the same for both ATP∙Mg and ATP∙Mg∙Li 
stimulation.  However, the activation of the P2 receptor by the ternary complex of 
ATP∙Mg∙Li increases the length of time for Ca levels to return to baseline significantly 
more than ATP∙Mg (2.2-fold) indicating a change in the deactivation of the P2 receptor 
due to Li
+
 or slower Ca
2+
 reabsorption by internal Ca
2+
 stores.  This suggests that the 
addition of Li
+
 to ATP∙Mg modulates the P2 receptors in some way to elicit a slower 
return to basal Ca
2+ concentrations.  As mentioned, there are two types of P2 receptors; 
P2Y, a GPCR, facilitates Ca
2+
 release from intracellular stores, whereas P2X, an ion 
channel, allows extracellular Ca
2+
 to flow into the cell.  To distinguish whether the slower 
Ca
2+
 reuptake observed in the presence of ATP∙Mg∙Li ternary complex is due to P2X or 
P2Y, extracellular Ca
2+
 was removed from the buffer in the experimental conditions 
(Figure 3-13).  This was to solely test the P2Y response to stimuli.  The neuron was 
stimulated with ATP∙Mg followed by ATP∙Mg∙Li.  The result was that the Ca 
concentrations were the approximately the same upon stimulation with ATP∙Mg versus 
ATP∙Mg∙Li, shown by the same fluorescence intensities between applications, which was 
consistent with the previous microscopy experiments.  However, in the absence of 
extracellular Ca
2+
, stimulation with ATP·Mg·Li did not cause a slower P2 receptor 
deactivation over stimulation with ATP·Mg.  This result indicates that the P2Y 
component of the cellular response to ATP does not significantly change in the presence 
of Li
+
.  Thus, the slower deactivation or Ca
2+
 reuptake that the ATP∙Mg∙Li complex 
causes is likely through interaction with P2X receptors.  The stimulation by this ternary 





Figure 3-12.  Fluorescence response after 4 separate 20-second applications of either 100 
μM ATP·Mg (first and third application) or 100 μM ATP·Mg·Li (second and fourth 
application).  Extracellular calcium was in the buffer at a concentration of 2.5 mM.  
Fluorescent calcium indicator is Fluo-3.  Experiments were collected on a laser scanning 
confocal microscope.  The paired t-test indicates that ATP·Mg·Li evokes a significantly 




 response (ATP·Mg vs. 







 response (ATP·Mg vs. 2
nd
 ATP·Mg; internal control): n = 20; <t100-20> = 86, 88 
sec, σ = 63, 54 sec; p = 0.78).  Data was provided by Dr. Joseph Kao, University of 




Figure 3-13.  Fluorescence response after 4 separate 100-second applications of either 
100 μM ATP·Mg (first and third application) or 100 μM ATP·Mg·Li (second and fourth 
application). No calcium was in the extracellular buffer.  Fluorescent calcium indicator is 
Fluo-3 and represents intracellular calcium.  Experiments were collected on a laser 
scanning confocal microscope.  The P2Y component of ATP response does not depend 
significantly on Li
+




 response (ATP·Mg vs. ATP·Mg·Li): n = 28; 







 ATP·Mg; internal control): n = 28; <t100-20> = 41, 38 sec, σ = 33, 35 
sec; p = 0.73).  Data provided by Dr. Joseph Kao, University of Maryland School of 
Medicine.
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though preliminary, illustrates the need to explore the biological targets of Li
+
 in light of 
a fundamental biophysical model, which this Chapter seeks to provide.  The data 





 coordinate and bind together (Figure 3-14).  This paradigm-shifting 
hypothesis that Li
+
 acts in a complex with magnesium at magnesium-binding sites allows 
one to reconsider the wealth of biological data that has been collected over the last 
several decades in a new light.  For example, one can reconsider the many Mg-
phosphates, such as on ATP cofactors, or even Mg-carboxylates involved in biological 
processes, which are the subject of much of the previously explored literature in Li
+
 
research, and re-interpret the data through this model to gain new insights.  Many of the 
enzymes known to be inhibited by Li
+
 at physiologically relevant concentrations, such as 
glycogen synthase kinase 3β (GSK3β) and inositol monophosphatase (IMPase), require 
both ATP and Mg
2+
 binding (often two or three metal binding) for critical for enzyme 
activity and could be sites where, instead of Mg
2+
 displacement, a ternary complex of 
ATP∙Mg∙Li acts (see Chapter 6).  
In putting forth a new basic molecular hypothesis of Li
+
’s action in biology, a 
foundation has been laid for guiding new directions in Li
+
 research, which could uncover 
new potential drug targets, assist in better drug design, and possibly finally get to a 
fundamental understanding of the underlying causes of BD.  The preliminary neuronal 
evidence leads to one such new target of Li
+
 action, e.g., cellular membrane surface 
receptors, such as P2X receptors, which are involved in cellular stress and activated 




Figure 3-14. Possible model for the ternary complex of triphosphate, magnesium (peach) 
and lithium (blue).  Mg
2+
 is hexacoordinated and shown to coordinate to the β and γ 
phosphates via dehydration of two water molecules.  Li
+
, which is tetracoordinated, is 





mechanism of lithium action is the best starting point for biological and, eventually, 
clinical studies. 
 
Materials and Methods 
NMR Sample Preparation 
NMR samples were prepared in 5 mm NMR tubes (Wilmad Labglass) with a 
H2O/ D2O (90%/10%) mixture to a final volume of 500 L (Deuterium Oxide from 
Cambridge Isotope Laboratories, Inc.).  Dry stocks of ATP, adenosine diphosphate, 
guanosine triphosphate, and guanosine diphosphate as sodium salts (Sigma-Aldrich) were 
dissolved in water, adjusted to pH 8.0 with NaOH and stored at -20°C in 100 mM 
aliquots until ready for use.  A standard pH Meter and probe were used from Beckman 
ϕpH Meter; Orion pH Electrode from Thermo Scientific.  Samples were prepared in 
NMR Buffer (25 mM sodium chloride and 1 mM sodium cacodylate, pH 6.5) from a 10x 
stock.  Sodium chloride, sodium cacodylate, lithium chloride solution (8M), magnesium 
chloride 6-hydrate, manganese chloride (II) tetrahydrate were purchased from Sigma-
Aldrich.  Unless otherwise stated, NMR samples contained 10 mM ATP (50 μL of 100 
mM stock), 11 mM MgCl2 (5.5 μL of 1M MgCl2 stock), 10 mM LiCl (5 μL of 1M LiCl 
stock), with or without 50 μM MnCl2 (2.5 μL from 10 mM MnCl2 stock), 50 μL D2O, 
and the remaining volume up to 500 μL was NMR Buffer. 
 
NMR Data Collection 
Data were collected on either a Bruker 600 MHz AVANCE spectrometer with a 
Broadband Observe (BBFO) probe located at the IBBR or a Bruker 600 MHz AVANCE 
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spectrometer equipped with a Broadband Inverse probe located at the NIST.  Datasets 
were collected at 283K (9.85°C), 298K (24.85°C), 300K (26.85°C), 303K (29.85°C), or 
310K (36.85°C) and data are presented in the text with specific temperatures of 
acquisition.   
 
7
Li T1 Relaxation Measurements 
One dimensional 
7
Li NMR inversion recovery experiments to measure T1 
relaxation used the following experimental acquisition parameters unless otherwise noted 
in the text: pre-delay (D1) of roughly 5 times the 
7
Li T1, which was measured at each 
temperature and typically exceeded 100 sec.  The total digitization (TD) was 4096 points, 
sweep width 699.63, dummy scans (DS) = 4, number of scans (NS) = 8, with a 
spectrometer frequency of 233.233 MHz for lithium at 14.4 Tesla (600 MHz proton 
frequency spectrometer).  The variable delay list was kept constant for comparable sets of 
experiments but may otherwise be different depending on the expected relaxation rate 
(i.e. experiments at different temperatures).  Spectra collected at different delay times 
were processed with the same zero filling to 2X the number of data points and apodized 
with experimental multiplication using 2.0 Hz line broadening and phase corrected based 
on the zero time delay of the variable delay.   The lithium signal was peak picked, the 
peak height and integrated volume of the signal was then measured and plotted for each 
experiment at the different variable delays to allowing a fitting to a T1 relaxation rate 
using Topspin 1.3 with the following commands: ‘xf2’, ‘t1guide’, ‘extract slice’ from Fid 
number 32, ‘define ranges’ to obtain integral, export region to relaxation module, 
‘relaxation window’ to plot data, fit the data. 
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Lithium Titration Binding Measurements by NMR 
Li binding affinity to ATP was determined by a series of 
7
Li inversion recovery 
experiments measuring the 
7
Li T1 relaxation with increasing concentrations of ATP•Mg 
(Mn).  The Bruker automation software, IconNMR, was used with the Bruker automation 
hardware, NMR Case, for acquisition of the multiple samples required in these 
experiments.  The T1 relaxation was determined using the Topspin ‘T1Guide’ program, 






P 1D experiments used a zero go pulse program with the Broadband probe 
tuned to 242.93 MHz for phosphorus at 14.4 Tesla (600 MHz proton frequency 
spectrometer), number of scans (NS) = 1024, dummy scans (DS) = 4, and total 
digitization (TD) = 8192.  Spectra were process with zero filling to 2X the number of 




]i Measurements on Rat Neurons 
Male Sprague-Dawley rats, weighing 150-250 kg, were purchased from Harland 
Laboratories (Frederick, MD) and killed by CO2 asphyxiation, as approved by the 
Institutional Animal Care and Use Committee of the University of Maryland 
Biotechnology Institute.  Dissociation of nodose ganglion neurons (NGNs) was 
performed as described previously [111] with the exception that sterile technique was 
used and the final neuronal pellet was resuspended in Leibovitz L-15 medium (Gibco-
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BRL, Grand Island, NY) containing 10% fetal bovine serum (FBS; JRH Bioscience, 
Lenexa, KS).  The resulting cell suspension was plated as 0.2 mL aliquots onto 25-mm 
glass coverslips (Fisher Scientific, Newark, DE) coated with poly-D-lysine (0.1 mg/mL; 
Sigma, St. Louis, MO).  NGNs were incubated at 37°C for 24 h, maintained at room 
temperature to prevent neurite outgrowth, and used for experiments for 72 h.  NGNs were 
loaded with fluo-3 by incubation with the acetoxymethyl (AM) ester of fluo-3, as 
previously described [85].  During imaging experiments, the neurons were superfused 
with Locke solution containing the following (in mM): 120 NaCl, 3.0 KCl, 1.5 MgCl2, 
1.0 NaH2PO4, 25 NaHCO3, 2.5 CaCl2, and 10.0 dextrose; the solution was equilibrated 
with 95% O2-5% CO2 to reach a final pH of 7.4.  Where nominally Ca
2+
-free solution 
was required, CaCl2 was replaced with an equivalent amount of MgCl2.  P2 receptor 
activation was induced by exposure to 100 μM ATP, 100 μM MgCl2, and 1 mM LiCl in 
the superfusate as specified in the data.  A laser scanning confocal microscope was used 
to image changes in fluo-3 fluorescence elicited by agonist challenges in the NGNs.  
Fluorescence excitation was at 490 nm and other experimental parameters with Fluo-3 
detection were performed as described previously [85].  The fluorescence intensity was 
recorded relative to the baseline fluorescence (ΔF/F0).  Student’s t-test was applied to the 
data to determine significance between two means, as described in [85]. 
 
Structures 
ATP, DPG, Triphosphate, and EDTA structures were built using ChemBioDraw 
(Perkin Elmer) and Microsoft Powerpoint.  Figures were refined using CorelDraw X7 






ATP·Mg·Li binds as a Ternary Complex 



















As was introduced in Chapter 1, each year, BD affects approximately 6.1 million 
American adults, ages 18 and older [112, 113].  Li
+
 was first introduced as a treatment for 
BD over 50 years ago and, despite advancements in pharmaceuticals, is still considered 
the ‘gold standard’ for effective treatment of this illness.  Unfortunately, Li
+
 also has a 
number of negative side effects, such as kidney and thyroid toxicity, which make it less 
than an ideal drug.  Other drawbacks to Li
+
 treatment include the challenge of non-
compliance from patients, the narrow gap between efficacy and intoxication, and effects 
on unborn children and nursing infants [1, 52].  The molecular mechanism(s) of such a 
simple, yet effective, medication with such harmful side effects still needs to be 
understood in terms of both the cellular target(s) of Li
+
, and the transport and distribution 
of Li
+




Lithium carbonate or lithium citrate is administered in the form of an oral tablet 
and the drug is absorbed in the small intestine for a standard formulation, or in the small 
or large intestine for a slow-release formulation.  Experiments measuring gastrointestinal 
epithelial cells upon acute exposure to Li
+
 confirmed cellular influx to be through passive 
diffusion down its electrochemical gradient [74].   Li
+
 is filtered from the blood through 
the kidneys for either excretion from the body or reabsorption by the body.  During fluid 
filtration in the lumen, about 60 percent of Li
+
 is reabsorbed in the proximal tubule to 
circulate in the bloodstream, while about 25 percent is excreted in the urine [74, 114].  
The transport and distribution of Li
+
 are not well understood.  Because Li
+
 is absorbed 
96 
and circulates through the bloodstream, the following research considers the protein 
serum albumin as a protein with which Li
+
 might interact in the blood plasma. 
Human serum albumin (HSA) is the most abundant protein in the blood plasma at 
a concentration of approximately 0.6 mM [115].  Physiologically, HSA regulates plasma 
oncotic pressure (i.e., the osmotic pressure in a blood vessel's plasma that tends to pull 
water into the circulatory system) and assists in cellular repair at cell membranes by 
shuttling fatty acids to and from sites of cellular damage [116, 117].  In addition to fatty 
acids, HSA binds and transports hormones, bilirubin, heme, metal ions, and certain drugs, 
delivering these molecules through the bloodstream  [118, 119].  Of particular interest 
and importance to the pharmacological community is understanding fatty acid binding 
and drug binding properties of HSA.  It is known that there are two preferred binding 
sites for small molecule drugs on HSA, Site I and Site II, referred to as Sudlow Sites [86, 
119] (Figure 4-1).  While both sites bind to aromatic molecules, Site I has been observed 
to more specifically bind bulky molecules with a centralized negative charge, while Site 
II has been found to prefer binding to extended conformations of molecules with a 
negative charge at one end of the ligand [120, 121].  Furthermore, HSA has identified 
seven fatty acid sites [122]: sites 2, 4, and 5 bind to fatty acids with relatively higher 
affinity, while sites 1, 3, 6, and 7 bind fatty acids with a relatively lower affinity, thereby 
allowing for the possibility of competition with other ligands or drugs at these lower 
affinity binding sites [122]. 
Though not extensively reported in the literature, the binding of ATP to HSA, as 
well as bovine serum albumin (BSA), has been studied under various conditions using   
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Figure 4-1.  Human serum albumin (HSA) is shown as a ribbon diagram (green) with 
fatty acids (FA) (red) bound to seven fatty acid sites on HSA.  Drug binding sites are 
labeled as Sudlow’s Site I, occupied by FA7, and Sudlow’s Site II bound to FA3 and 
FA4.  The coordinates were retrieved from the PDB entry 1E7H.  The image was 
rendered in PyMol.
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several methods.  Ultrafiltration and equilibrium dialysis experiments demonstrated that 
ATP binds to HSA, and that the binding affinity decreases with increasing pH [123].  
Electron Spin Resonance (ESR) verified the specific binding of spin-labeled derivatives 
of ATP to BSA [124].  ATP binding to BSA was also studied by NMR and ultrafiltration, 
and was found to occur with a stoichiometry of 1:1, and a KD of 40 μM at pH 6.4 and a 
KD of 120 μM at pH 7.4 [125]; this interaction exhibits a similar pH dependence as the 
one discussed above for HSA.  Furthermore, the structure that ATP·Mg adopts when 
bound to BSA was probed using 
1
H-NMR TRNOESY and was found to be similar to the 
conformation it assumes when bound to several enzymes that bind ATP [126].  
31
P NMR 
diffusion studies have also shown that ATP in the absence of Mg
2+
 binds both HSA and 
BSA at low affinity binding sites [127].  Although crystal structures have been solved for 
HSA in the apo form [128] and with 5 fatty acids bound [129], and for BSA [130, 131], 
to date, no structure of HSA with ATP bound has been solved.  Thus, it is not known 
whether ATP binding occurs at Site I, Site II and/or some other as yet identified site.  
As described in Chapter 3, our work has shown that Li
+
 can form a ternary 
complex with Mg
2+
 and ATP.  Taking a reductionist approach, and building on this basic 
finding, the research presented in this Chapter is aimed at exploring the integrity of this 
ternary complex in the presence of HSA and identifying any effect Li
+
 might have on the 
binding of ATP to HSA.  In particular, we sought to determine if the ternary ATP·Mg·Li 
complex is maintained in the presence of HSA, how its structure might change in the 




Results and Discussion 
Although it has been suggested that Li
+
 could bind directly to serum proteins, to 
date, no direct evidence of such an interaction has been measured.   In light of our 
findings that Li
+ 
could form a complex with ATP·Mg, the possibility that Li
+
 binding to 
proteins, like HSA, might be mediated through an intermediary, such as a nucleotide 
ligand, seemed quite plausible.  Here, we used a number of techniques that could 
interrogate the binding of Li
+
 to ATP·Mg in the presence of HSA to investigate the 
potential of the ternary complex further binding to HSA (Figure 4-2).   





While ATP and ATP·Mg have been shown to bind to HSA, the effect of Li
+
 on this 





, Water ligand-observed gradient spectroscopy (WaterLOGSY) 
NMR experiments were performed (see Chapter 2 for details).   Briefly, in this 
experiment, which is commonly used to screen drug compounds for binding to a protein, 
magnetization of bulk water is transferred to the hydration shell of the ligands and bound 
protons of the protein and ligands.  Since free ligands have a longer relaxation time than 
those that are bound to the protein, the two possibilities for the ligand (e.g. free versus 
bound) can be distinguished from each other.   
A negative control experiment was first carried out to test the WaterLOGSY 
experimental set-up.  A WaterLOGSY of HSA and the small molecule, DPG, which we 
have previously determined, through indirect measurements using 
7
Li T1, to have no 




Figure 4-2.  Scheme of Li
+




Figure 4-3.  
1
H NMR Spectra of a 0.5 mM HSA sample with 10 mM DPG, 11 mM Mg, 
and 10 mM LiCl as reference (blue) and the WaterLOGSY (red).  The chemical shift of 
the DPG is indicated with an asterisk in the inset spectrum.  These spectra were collected 
on a 600 MHz NMR spectrometer.  
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DPG Experiments at 283 K on 500 MHz NMR 
BSA DPG Mg Li Mn 
7
Li T1 Relaxation (s)  
+ + + +  - 6.97 
-  + + +  - 7.65 
+ + + + + 6.07 




Table 4-1.  
7
Li T1 relaxation NMR experiment with 2,3- Diphosphoglycerate (DPG) and 
Bovine Serum Albumin (BSA).  Experiments were collected on a 500 MHz NMR 
spectrometer at 283 K.
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spectrum in blue shows a large 
1
H signal for DPG at approximately 4.0 ppm.  In the 
WaterLOGSY, the low positive signal at 4.0 ppm indicates there is very weak, if any, 
binding of DPG to the HSA (red spectrum).  This result was also consistent with 
7
Li T1 
relaxation data (Table 4-1).  The 
7
Li relaxation in a sample of 10 mM DPG, 11 mM 
MgCl2, and 10 mM LiCl was 7.65 seconds.  The addition of 0.5 mM BSA decreases the 
7
Li relaxation only slightly to 6.97 seconds.   Similar 
7
Li relaxation times in the presence 
and absence of BSA suggests that either the DPG·Mg·Li complex does not bind, or binds 
very weakly.  The confirmation of weak or no binding of DPG to BSA supports the 
WaterLOGSY finding and verifies that the experimental parameters are correct. 





 ions (Figure 4-4).  A 1D 
1
H reference spectrum of 0.5 mM 
HSA, 10 mM ATP, 11 mM MgCl2, and 10 mM LiCl, for the WaterLOGSY, is shown in 
blue.  The WaterLOGSY spectrum shows the positively phased signals of the protons of 





.   As the magnitude of the observed ATP signals in the WaterLOGSY for the 
experiments carried out with ATP alone, ATP·Mg and ATP·Mg·Li were all qualitatively 
similar, it can be concluded that Li
+
 does not significantly inhibit ATP from binding to 
HSA. 
Equilibrium gel filtration experiments also support the finding that ATP·Mg binds 
to HSA in the both presence and absence of Li
+
.  Equilibrium gel filtration measures 
ligand binding to protein by detecting the depletion of ligand from the ligand-equilibrated 





Figure 4-4.  
1
H NMR spectra of the sample in the reference (blue) and the saturation 
transfer in the WaterLOGSY (red) indicating that ATP binds to the macromolecule, HSA.  
Experiments were taken on a 600MHz NMR Spectrometer.  All of the remaining 
unlabeled peaks in the reference spectra can be attributed to protons on HSA.
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gel filtration column was equilibrated with 1 mM ATP and 1.1 mM MgCl2 (Figure 4-5).  
HSA was loaded on the column and eluted between 7 and 12 mL elution volume, as 
detected by UV absorbance at 280 nm.  The high concentration of ATP in the buffer and 
addition of protein cause the UV detector to reach the high detection limit, noticeable at 
the top of the protein elution peak.  Following the elution of the HSA-ligand complex, 
whose elution times was also between 7 and 12 mL elution volume and was overlapped 
and indistinguishable with the peak from HSA, the chromatogram showed a trough, at 
approximately 16 to 18 mL, representing the depletion of the ATP from the equilibration 
buffer that results due to ATP binding to HSA.  The elution of ATP appears as negative 
signal because the concentration of ATP in the elution volume is less than the 1 mM 
baseline at which the column was equilibrated.  The gel filtration results, therefore, 
clearly further confirm that ATP binds to HSA in the presence of Li
+
.  In addition, the gel 
filtration data show that the presence of Li
+
 has no appreciable effect on ATP binding to 
HSA (Figure 4-6).  While both the NMR and gel filtration data were not interpreted in a 
quantitative fashion, both sets of data qualitatively support the conclusion that Li
+
 does 
not appear to significantly modulate the interaction of ATP with HSA. 
Mg
2+
 Binds to ATP in the Presence of Albumin 
Phosphorus nuclei can be directly detected by 
31
P-NMR to probe the chemical 
environment of the triphosphates of ATP.  Changes in the magnetic field of a particular 
nucleus due to neighboring or nearby nuclei can be detected by NMR as chemical shift 
perturbations (see Chapter 2 for details).  The alpha (α), beta (β), and gamma (γ) 
phosphates of ATP are presented as stacked spectra collected under various sample 




Figure 4-5.  Overlay of three separate Equilibrium Gel Filtration chromatograms: 200 
μM HSA (black), 400 μM HSA (pink), 600 μM HSA (blue).  The HSA dimer is shown to 
elute at approximately 8 mL elution volume, followed by HSA monomer at 
approximately 10 mL, and a trough appears at the ATP elution volume of approximately 
17 mL.  The ATP elution (inset) appears as a trough due to ATP binding with HSA and 




Figure 4-6.  Overlay of three separate Equilibrium Gel Filtration chromatograms: 400 
μM HSA (black), 600 μM HSA (purple), 800 μM HSA (blue).  The HSA dimer is shown 
to elute at approximately 8 mL elution volume, followed by HSA monomer at 
approximately 10 mL, and a trough appears at the ATP elution volume of approximately 
17 mL.  The ATP elution (inset) appears as a trough due to ATP binding with HSA and 
depletion from the buffer.  The equilibration buffer for all samples contained 1 mM ATP, 
1.1 mM MgCl2, and 1 mM LiCl.  Note that the 600 μM HSA (purple) absorbance shift 




Figure 4-7.  
31
P NMR Spectra of 5 mM ATP and 1 mM HSA alone and with the addition 
of MgCl2, LiCl, and MnCl2.  The phosphates of ATP are labeled alpha, beta, and gamma 
in the top spectrum.  Specific concentrations for each spectrum are labeled to the left of 
each spectrum.  These spectra were collected on a 600 MHz NMR Spectrometer at 303 
K.
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experiments, to highlight the observed chemical shift perturbations.  The bottom 
spectrum shows the signal positions for the three phosphates of ATP in the presence of 
HSA in the absence of metals.  The other three phosphate spectra include the addition of 
metals as specified in the figure (e.g., MgCl2, LiCl, and MnCl2).  A downfield chemical 
shift is observed for all phosphorus signals upon addition of MgCl2 to the HSA-ATP 
sample.  This is indicative of Mg
2+
 binding to the ATP in the presence of albumin.  
Further, the phosphate chemical shifts associated with ATP·Mg·Li directly aligned with 
the phosphate chemical shifts observed in the presence of HSA (Figure 4-8).  What is 
clear from the spectra is that HSA, while causing a broadening of the phosphorus signals, 
as might be anticipated upon binding of ATP to HSA, does not significantly perturb the 
phosphate chemical shifts.  This may suggest that the ATP binding interaction with HSA 
occurs via the adenosine-ribose, while the phosphates are directed outwards.  Therefore 
the phosphates may be less affected by the HSA interaction.   Nonetheless, it supports the 
conclusion that the ATP phosphates coordinate Mg
2+
 when ATP is bound to HSA in a 
manner that is similar to the way the phosphates of ATP free in solution coordinate Mg
2+
.     
As a control for all experiments involving ATP and HSA, the integrity of the ATP 
in the presence of HSA was also evaluated by 
31
P-NMR.  Comparison of a newly made 
sample and the same sample 5 days later revealed that the samples containing HSA 
slowly degraded over several days into ADP (Figure 4-9; Figure 4-10).  The ADP peaks 
are difficult to see between the α and γ phosphates, but the increase in peak height of 
inorganic phosphate is evident.    For this reason, freshly prepared samples were used for 







P NMR Spectra of 5 mM ATP and 5 mM Li alone (top), with 5.5 mM Mg 
and 25 μM Mn (middle), and with the addition of 0.5 mM HSA (bottom).  The phosphate 
signals of ATP are labeled as alpha, beta, and gamma on the top spectrum with the 
addition of inorganic phosphate labeled on the bottom spectrum.  Specific concentrations 
for each spectrum are labeled to the right of each spectrum.  These spectra were collected 








P NMR spectra of 10 mM ATP, 11 mM MgCl2, 10 mM LiCl with 0.5 mM 
BSA on the day the sample was prepared (bottom) and five days later (top).  The 
phosphates of ATP (alpha, beta, and gamma) and inorganic phosphate are labeled in the 





Figure 4-10.  
31
P NMR spectra of 5 mM ATP, 5 mM LiCl (orange), with the addition of 
5 mM MgCl2, and 25 μM MnCl2 (blue), and the addition of 0.5 mM HSA (green).  Two 
spectra are in the absence of MnCl2 (black), and in the absence of HSA and MnCl2 (red).  
The phosphate signals of ATP are labeled as alpha, beta, and gamma on the top spectrum 
with the addition of inorganic phosphate, adenosine monophosphate (AMP), and 
adenosine diphosphate (ADP) labeled on the bottom spectrum.  Specific concentrations 
for each spectrum are labeled to the right of each spectrum.  All of these spectra were 
collected at on a 600 MHz NMR Spectrometer at 283 K.
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ATP·Mg·Li Ternary Complex Structure in the Presence of Albumin 
7
Li NMR can provide a direct report of Li
+
 in a molecular complex.  By 
measuring shifts in the ensemble population of Li
+
 ions, NMR can reveal the binding 
behavior of Li
+
 through measurements such as T1 relaxation properties, which are 
expected to vary when comparing ions that are bound to molecular targets versus ions 
that are free in solution (see Chapter 2 for details).   Li
+
 binding to ATP·Mg in the 
presence of HSA was therefore further probed by 
7
Li T1 relaxation (Table 4-2).  Such 
relaxation measurements can provide further evidence to support the conclusion that ATP 




 and that these two metals do not significantly 
inhibit ATP binding to HSA.  The 
7
Li T1 relaxation of Mg·Li in solution at 283 K is 
12.80 s, while the ATP∙Mg∙Li has a 
7
Li T1 of 6.70 s.  The shorter T1 observed upon 
addition of ATP points to Li
+
 binding to a larger molecule, namely ATP∙Mg.  The 
addition of HSA to ATP∙Mg∙Li results in a faster 
7
Li relaxation time of 2.985 s.  Li
+
 does 
not bind to HSA directly, shown by 
7
Li T1 control data of 12.702 s in the presence of 5 
mM LiCl, 5.5 mM MgCl2, and 0.5 mM HSA, nearly matching the 
7
Li relaxation time of 
free Li
+
.  Therefore, the 
7
Li T1 relaxation data, shown in Table 4-2, indicates that ATP is 
binding directly to the HSA and Li is carried onto the HSA via ATP. 
Paramagnetic relaxation enhancement (PRE) is a method to probe the binding 
environment of the Li
+
 to discover whether Mg
2+
 is in close proximity to the detecting 
nucleus, in this case Li
+
.  The paramagnetic ion, Mn2+, is added to the sample in a very 
small quantity and rapidly exchanges with Mg
2+
, sampling all of the Mg
2+
-binding sites, 
and causing a faster relaxation of neighboring nuclei (refer to Chapter 2 for details).   
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7
Li T1 Relaxation at 600 MHz 
HSA ATP Mg Li Mn 283K 
- - + + - 12.80 
- - + + + 12.13 
Relaxation Enhancement (%) 5.3 
      
- + + + - 6.70 
- + + + + 2.62 
Relaxation Enhancement (%) 60.9 
      
+ + + + - 2.99 
+ + + + + 0.48 
Relaxation Enhancement (%) 84.0 
      
0.5 mM 10 mM 11 mM 10 mM 50 μM  
 
Table 4-2.  
7
Li T1 relaxation experiments with 0.5 mM HSA, 10 mM ATP, 11 mM 
MgCl2, 10 mM LiCl in the presence or absence of 50 μM MnCl2 at 283K.  Controls in the 
absence of HSA or HSA and ATP are also shown.  Relaxation Enhancement (%) was 
calculated by subtracting the PRE (+ MnCl2) T1 value from the initial T1, dividing the 
difference by the initial T1, and multiplying by 100.  Experiments were collected on a 
600 MHz NMR spectrometer.
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Under these sample concentrations, Li
+
 can be shown to bind to ATP·Mg in the 
presence of HSA by the observation of a PRE upon addition of Mn
2+
.  Indeed, at 283 K, 
the 
7
Li T1 dropped approximately 6-fold from 2.99 s to 0.48 s.  While HSA has been 
shown to bind zinc, copper, cadmium, and nickel metal ions, high affinity Mg binding 
has not been reported [132].  The 
7
Li T1 PRE observed in the presence of HSA and 
ATP∙Mg∙Li can be attributed to Li
+
 binding in close proximity to ATP∙Mg on HSA rather 
than at a Mg
2+
 site on HSA.  An interesting observation is the free ATP has a lower 
relaxation enhancement, 60.9 percent, than the HSA-bound, 84.0 percent (Table 4-2).  
This indicates that the Li local environment is slightly different in the free and albumin-
bound ATP∙Mg states.  Perhaps the structure of the phosphate tail of ATP, while still 
freely accessible to Mg∙Li, may change slightly when bound to albumin.  The Sudlow 
sites of HSA, where it has been suggested that ATP may bind, are reported to bind either 
heterocyclic anions or aromatic carboxylates [87].  Based on the known interactions at 
these sites, it is reasonable to propose that the adenosine and/or ribose directly interface 
with HSA at one or more of these sites, leaving the phosphate tail free to be 
unconstrained and adopt a pseudo-free state according to the NMR observable, 
7
Li, only 




 at the binding pocket. 
The PRE experiment reinforces that Li
+
 is bound to HSA by way of the ATP 
nucleotide.  In addition, it can be concluded that Li
+
 is bound in close proximity to Mg
2+
 
that is in turn bound to the albumin∙ATP, shown by the 
7
Li T1 PRE upon Mn
2+
 addition.  
To verify that these 
7
Li T1 interactions are specific and not randomly diffusing into 
contact with Mn
2+
 to cause a PRE 
23
Na T1 control measurements result in no change in 
T1 relaxation in the presence of Mn
2+




Na T1 Relaxation (ms) NMR Experimental Controls at 600 MHz 
HSA ATP Mg Li Mn 283 K 298 K 303 K 310 K 
+ + + + -  37.59 51.20 55.42 61.69 
+ + + + + 36.70 50.28 54.51 60.66 
 Relaxation Enhancement (%) 2.4 1.8 1.6 1.7 
         
+ -  + +  - 39.03 53.24 57.88 64.25 
+ -  + + + 39.09 53.25 58.12 64.22 
 Relaxation Enhancement (%) -0.2 0.0 -0.4 0.0 
         
-  + + + -  37.82 52.14 56.27 63.27 
-  + + + + 38.18 52.65 57.27 63.86 
 Relaxation Enhancement (%) -0.1 -1.0 -1.8 -0.9 
         
- - + + - 41.303 56.215 61.112 67.930 
- + - + - 28.285 39.067 42.488 47.245 
0.5mM 5mM 5.5mM 5mM 25μM 
     
Table 4-3. 
23
Na (sodium) T1 relaxation control NMR experiments with 5 mM ATP were 
observed at 283 K, 298 K, 303 K, and 310 K. Relaxation Enhancement (%) was 
calculated by subtracting the PRE (+ MnCl2) T1 value from the initial T1, dividing the 
difference by the initial T1, and multiplying by 100.  Experiments were collected on a 
600 MHz NMR spectrometer.
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Taken together, the data in this chapter supports the model that an ATP·Mg·Li 
complex can remain intact upon binding to a cofactor site on a protein (e.g., the ATP 
binding pocket on HSA) and that the structure of this complex may be little perturbed.   
Based on these observations, it can be envisioned that Li
+
 operates by ‘piggy backing’ on 
phosphate containing ligands, like ATP·Mg, to enable both transport within the body as 
well as targeting of sites on specific protein.  In this sense, if Li
+
 is viewed through the 
lens of a molecule entity, like ATP, one can begin to think about how targeting of Li
+
 in 
the body may be achieved. 
Unanticipated Differences in ATP Binding to BSA and HSA 
A large difference in 
7
Li T1 relaxation was initially observed for ATP·Mg·Li 
complex in the presence of HSA versus BSA (
7
Li T1 data not shown).  This observation 
led to the question of whether ATP bound to HSA in significantly different mode and/or 
with a significantly different affinity than BSA, which would cause the 
7
Li T1 relaxation 
to change.  However, further examination of different HSA and BSA samples by 
7
Li T1 
relaxation experiments were unable to consistently reproduce the large differences and 
instead showed little variability between HSA and BSA (Table 4-4).  The amino acid 
sequence alignment of HSA and BSA shows an approximately 76% sequence identity 
between BSA and HSA.  In addition, the highly conserved residues found specifically at 
the known Sudlow sites where ATP is likely to bind render it improbable, though not 
impossible, that there would be fundamental differences in ATP binding to HSA versus 
BSA (Figure 4-11).  Over the course of collecting the 
7
Li T1 relaxation of several 
samples, it became apparent that seemingly inconsistent variation was seen within 
samples of the same species, human or bovine (Table 4-5).  To account for the  
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NMR Experiments at 298 K - 600 MHz NMR 
HSA BSA ATP Mg Li Mn 
7
Li T1 Relaxation 
(sec) 
Product # 
- + + + + - 8.885 ± 0.125 A6003 
- + + + + + 3.099 A6003 
        
+ - + + + - 6.596 ± 1.23 A3782 


















Li T1 relaxation of samples containing either BSA or HSA.  Standard 
deviation is shown where experiments were run in triplicate.  Experiments were collected 
on a 600 MHz NMR spectrometer at 298K.
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Figure 4-11.  Amino acid sequence alignment of HSA (Sigma-Aldrich Product #A3782) 
and BSA (Sigma-Aldrich Product #A6003) using the NCBI Basic local alignment search 
tool (BLAST).  HSA and BSA have a 76% sequence identity.  Identical amino acids 
(black background) and similar amino acids (grey background) of HSA and BSA are 
shown.  Subdomain IIA (pink) and subdomain IIIA (blue) are highlighted.  Amino acid 
residues involved in Sudlow’s Site I (orange asterisk) or Sudlow’s Site II (green asterisk) 
are identified [86, 119].
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7




Li T1 Cat. # HSA·ATP∙Mg∙Li Mn 
7
Li T1 Cat. # 
+ - 8.467 A6003 + - 3.746 A3782 
+ - 9.331 A6003 + - 6.291 A3782 
+ - 8.856 A6003 + - 6.371 A3782 
+ + 3.099 A6003 + - 6.693 A3782 
+ - 4.075 A7030 + - 7.612 A3782 
+ - 3.629 A7030 + - 6.638 A3782 
+ - 4.228 A7030 + - 8.092 A3782 
+ + 2.330 A7030 + - 7.325 A3782 
+ - 8.177 A1900 + - 4.041 A3782 
+ - 11.357 A7960 + - 3.791 A3782 
 
+ + 0.651 A3782 
+ + 2.361 A3782 
+ + 2.874 A3782 
  
Table 4-5.  
7
Li T1 relaxation experiments of samples containing: 0.5 mM BSA (left 
table) or 0.5 mM HSA (right table), 10 mM ATP, 11 mM MgCl2, 10 mM LiCl in the 
presence or absence of 50 μM MnCl2 at 298 K.  The units for the T1 time are in seconds.  
The catalog number refers to the Sigma-Aldrich product number.  Experiments were 
collected on a 600 MHz NMR spectrometer. 
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differences in T1 relaxation between samples, the quality of the different albumin 
products that were used was assessed. 
There are numerous products of albumin protein sold by Sigma-Aldrich.  
Differences between products in the amino acid sequences, purification procedures, and 
final processing and purity of the protein product were sought (Table 4-6; Table 4-7; 
Table 4-8; Table 4-9).  From this data, it can be inferred that the differences in 
7
Li T1 
relaxation times between albumins may be due to interference from globulin, a small 
protein found in serum.  The primary HSA that we used was globulin-free (Sigma-
Aldrich Cat # A3782) and the main BSA that we used was not labeled globulin-free 
(Sigma-Aldrich Cat # A6003).  An overlay of the HSA structure with and without fatty 
acids shows some significant differences in the trajectories of the helices (Figure 4-12).  
Such differences in structure, particularly with respect to Sudlow sites, for the different 
ligand bound states of HSA, highlight the likely reason why the ATP affinity for these 
sites may vary between albumin samples tested.  Those differences in affinity would be 
reflected in the T1 relaxation.  
Gel filtration results provided further evidence of differences in ATP binding 
between HSA and BSA (Figure 4-13).  ATP binds to BSA with weaker affinity than ATP 
binds to HSA, as shown by the shallower trough of ATP at approximately 17.5 mL 
elution volume.  Also, the elution profiles of BSA and HSA by gel filtration show that the 
ratio of monomer to dimer is much higher in HSA than BSA.  Perhaps the ATP binding 
site is inaccessible or less accessible in dimer form.  If this is the case, then the higher 
population of dimer in BSA would likely account for lower ATP binding to BSA over 
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Table 4-6.  Serum Albumin purification processing categorized by Sigma-Aldrich 
product number [133].
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A3782 Human, pooled 66,528 585 
A1653 Human, pooled 69,363 609
*
 
A9731 Human, recombinant 66,468 585 
A7030 Bovine, pooled 66,429 583 
A6003 Bovine, pooled 66,429 583 
A7906 Bovine, pooled 69,289 607
*
 
A1900 Bovine, pooled 66,429 583 
 
 
Table 4-7.  List of serum albumin proteins sold by Sigma-Aldrich.  The proteins with an 
asterisk (*) contain a leader sequence that is a precursor to the mature HSA and is a 
localization signal directing albumin to the endoplasmic reticulum, Golgi apparatus, and 
ultimately secretion into the blood [134].
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Amino Acid Sequences of Sigma-Aldrich Human Serum Albumin 



































Table 4-8.  Amino acid sequences of Human Serum Albumin categorized by Sigma 
product number.
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Amino Acid Sequences of Sigma-Aldrich Bovine Serum Albumin 











A6003 Bovine, pooled; Same sequence as A7030 












A1900 Bovine, pooled; Same sequence as A7030 
 




Figure 4-12.  An overlay of the backbone structure of HSA bound by fatty acids (green 
ribbon) and HSA without any fatty acids (blue ribbon).  The structures were rendered 
from PDB files 1E7H and 1BM0, respectively.  For clarity of comparison of the protein 





Figure 4-13.  Overlay of two separate Equilibrium Gel Filtration chromatograms: 600 
μM HSA (black) and 600 μM BSA (red).  The HSA or BSA dimer is shown to elute at 
approximately 8 mL elution volume, followed by HSA or BSA monomer at 
approximately 10 mL, and a trough appears at the ATP elution volume of approximately 
17 mL elution volume.  The ATP elution (inset) appears as a trough due to ATP binding 
with HSA or BSA and depletion from the buffer.  Equilibration buffer contained 1 mM 
ATP, and 1.1 mM MgCl2 for both.
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but it is good to be aware that there are roughly 80 types of albumin, which are 
commercially available.   
 
Materials and Methods 
NMR Sample Preparation 
NMR samples were prepared in 5mm NMR tubes (Wilmad Labglass) with a H2O/ 
D2O (90%/10%) mixture to a final volume of 500 μL (Deuterium Oxide from Cambridge 
Isotope Laboratories, Inc.).  Dry stocks of adenosine triphosphate, adenosine 
diphosphate, guanosine triphosphate, and guanosine diphosphate with sodium salts 
(Sigma-Aldrich) were dissolved in water, adjusted to pH 8.0 and stored at -20°C in 100 
mM aliquots until ready for use.  A standard pH Meter and probe were used from 
Beckman ϕpH Meter; Orion pH Electrode from Thermo Scientific.  Samples were 
prepared in NMR Buffer (25 mM sodium chloride and 1 mM sodium cacodylate, pH 6.5) 
from a 10x stock.  Sodium chloride, sodium cacodylate, lithium chloride solution (8M), 
magnesium chloride, 6-hydrate, manganese chloride (II) tetrahydrate were purchased 
from Sigma-Aldrich.  Unless otherwise stated, NMR samples contained 10 mM ATP (50 
μL of 100 mM stock), 11 mM MgCl2 (5.5 μL of 1M MgCl2 stock), 10 mM LiCl (5 μL of 
1M LiCl stock), with or without 50 μM MnCl2 (2.5 μL from 10 mM MnCl2 stock), 50 μL 
D2O, and the remaining volume up to 500 μL was NMR Buffer. 
 
NMR Data Collection 
Data were collected on either a Bruker 600 MHz AVANCE spectrometer with a 
Broadband Observe (BBFO) probe located at the IBBR  or a Bruker 600 MHz AVANCE 
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spectrometer equipped with a Broadband Inverse probe located at the NIST.  Datasets 
were collected at 283K (9.85°C), 298K (24.85°C), 300K (26.85°C), 303K (29.85°C), or 
310K (36.85°C) and data are presented in the text with specific temperatures of 
acquisition.   
 
Water LOGSY Experiments 
One-dimensional 
1
H NMR WaterLOGSY experiments were acquired using 
published methods [89].  A reference experiment was collected first, followed by the 
WaterLOGSY saturation transfer spectrum.  Acquisition parameters for the 
WaterLOGSY spectra included a total digitization (TD) of 8192 points, sweep widths 
(sw) of 7507.507 Hz, dummy scans (DS) = 16, number of scans (NS) = 32, with a mixing 
time of 6.7 s.    NMR spectra were processed using Bruker Topspin (version 1.3) and 




Li T1 Relaxation Measurements 
One-dimensional 
7
Li NMR inversion recovery experiments to measure T1 
relaxation used the following experimental acquisition parameters unless otherwise noted 
in the text: pre-delay (D1) of roughly 5 times the 
7
Li T1, which was measured at each 
temperature and typically exceeded 100 sec.  The total digitization (TD) was 4096 points, 
sweep width 697.545, dummy scans (DS) = 4, number of scans (NS) = 8, with a 
spectrometer frequency of 233.233 MHz for lithium at 14.4 Tesla (600 MHz proton 
frequency spectrometer). The variable delay list was kept constant for comparable sets of 
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experiments but may otherwise be different depending on the expected relaxation rate 
(i.e. experiments at different temperatures). Spectra collected at different delay times 
were processed with the same zero filling to 2X the number of data points and apodized 
with experimental multiplication using 2.0 Hz line broadening and phase corrected based 
on the zero time delay of the variable delay.   The lithium signal was peak picked and the 
peak height and integrated volume of the signal then measured and plotted for each 
experiment at the different variable delays.  Either peak heights or volumes were then 
plotted and fit using a simple exponential to determine the T1 relaxation rate using 
Bruker Topspin 1.3 or 2.1. 
 
23
Na T1 Relaxation Measurements 
One-dimensional 
23
Na NMR inversion recovery experiments to measure T1 
relaxation used the following experimental acquisition parameters unless otherwise noted 
in the text: pre-delay (D1) of roughly 5 times the 
23
Na T1, which was measured at each 
temperature.  The total digitization (TD) was 2048 points, sweep width (sw) 1911.315 
Hz, dummy scans (DS) = 2, number of scans (NS) = 8, with a spectrometer frequency of 
232.72 MHz for lithium at 14.4 Tesla (600 MHz proton frequency spectrometer). The 
variable delay list was kept constant for comparable sets of experiments but may 
otherwise be different depending on the expected relaxation rate (i.e. experiments at 
different temperatures).  Spectra collected at different delay times were processed with 
the same zero filling to 2X the number of data points and apodized with experimental 
multiplication using 0.30 Hz line broadening and phase corrected based on the zero time 
delay of the variable delay.   The sodium signal was peak picked and the peak height and 
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integrated volume of the signal then measured and plotted for each experiment at the 
different variable delays.  Either peak heights or volumes were then plotted and fit using 






P 1D experiments used a zero go pulse program with the Broadband probe 
tuned to 242.93 MHz for phosphorus at 14.4 Tesla (600 MHz proton frequency 
spectrometer), number of scans (NS) = 1024, dummy scans (DS) = 4, and total 
digitization (TD) = 8192.  
31
P assignments for ATP, ADP, GTP, GDP, and triphosphate 






H 1D experiments used a zero go pulse program with the Inverse probe 
tuned to 600.23 MHz for phosphorus at 14.4 Tesla (600 MHz proton frequency 
spectrometer), number of scans (NS) = 1024, dummy scans (DS) = 4, and total 
digitization (TD) = 8192.  
1
H assignments for ATP were taken from reference data in the 




Gel Filtration Measurements 
The Equilibrium Gel Filtration technique (Hummel and Dreyer, 1962) was used to 
determine the dissociation constant between albumin (HSA and BSA) and ATP, in the 






).  An FPLC HiLoad 16/60 Superdex 
75 gel filtration column (GE Healthcare Life Sciences) was either equilibrated in running 
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buffer containing 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.4 mM KH2PO4 
and or NMR buffer, mentioned in the NMR Sample Preparation section (above), with 
ATP and Magnesium concentrations specified in the data figure at either 4°C or ambient 
temperature.  Then, different concentrations of albumin were incubated in the running 
buffer for a minimum of 10 minutes at room temperature, but were sometimes stored at 
4°C for up to 1 week. Following the incubation, the sample was loaded onto the column.  
The FPLC traces were followed using UV detection at 260nm and 280nm wavelength 
with two different detectors and the peak volumes from the traces were determined to 






Purine Receptor Explored for Functional 
Modulation by Interaction with 





P2X Receptor Background 
 
The modulation of membrane receptor response by ATP·Mg·Li observed in the 
neuronal cell assay, discussed in Chapter 3, sparked an interest in exploring the potential 
therapeutic action of Li
+
 with cell surface receptors.  It was reasoned that if the 
ATP·Mg·Li model is reflective of the physiological activity of Li
+
, then a receptor that 
requires ATP·Mg ligand binding, but not hydrolysis, for activation would be an ideal 
protein to test this hypothesis of lithium’s mechanism of action. 
ATP-activated purinergic (P2) receptors are involved in a diverse range of functions, 
including cardiopulmonary coordination, neuronal excitability, hearing, vision, pain, 
bacterial infection and cancer [136].  P2 receptors are ordered into two subclasses, P2X 
and P2Y, based on their structure and mechanism of signal transmission, where P2X 
receptors are ligand-gated ion channels and P2Y receptors are G-protein coupled 
receptors.  P2X receptors respond to nerve damage by stimulating pain and inflammation 
responses [137].  In the P2X subclass, there are seven types: P2X1, P2X2, P2X3, P2X4, 
P2X5, P2X6, and P2X7 (Table 5-1).  All of these ion channels have a similar basic 
architecture: intracellular amino- and carboxy-termini, a long extracellular loop, and two 
transmembrane spanning domains.  Within this family, the sequences are highly 
conserved, including ten cysteine residues in the extracellular loop, which are presumed 
to provide stability between subunits of P2X homo- and heterotrimers [138].  Sodium, 
potassium, and calcium ions flow through the ATP-activated pore opening of the P2X 
receptor [139].   
P2X receptor activation is sensitive to the structure of the agonist and studies have 
















P2X1 399 45 No Fast (< 1 s) 0.07 
P2X2 472 119 Yes Slow (> 20 s) 1.2 
P2X3 393 53 No Fast (< 1 s) 0.5 
P2X4 389 31 Yes Slow (> 20 s) 10 
P2X5 455 96 - Slow (> 20 s) 10 
P2X6 379 26 - Slow (> 20 s) 12 
P2X7 595 239 Yes Slow (> 20 s) 100 
 
Table 5-1.  Properties of the seven homomeric subclasses of the P2X family of 
purinergic ligand-gated ion channels [140-142].  Pore dilation refers to the larger ion 
channel opening upon prolonged or repeated stimulation by the agonist.  Channel current 
decay refers to the desensitization of the channel to the agonist as recorded by 
electrophysiology.  EC50 is the concentration of the agonist at 50% of the maximum 
response or effectiveness of the receptor to the agonist, in this case ATP. 
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3’-O-(4-benzoyl-benzoyl)-ATP (BzATP) as a mix of isomers with an EC50 of 20 μM is a 
stronger activator than ATP with EC50 of >100 μM [136].  Uridine 5’-triphosphate (UTP) 
and α, β-methylene-adenosine 5’-triphosphate (α,β-me-ATP) are less potent agonists than 
ATP [143].  Furthermore, differences in P2X activation and response time for 
desensitization are observed across different P2X subclasses.  Fully ionized, free ATP 
activates all P2X receptor channels to various degrees and the channels return to steady 
state at different rates.  The addition of magnesium results in activation for some 
channels and does not activate other channels [144].  Given this evidence, it is plausible 
that the presence of lithium at the ATP site on P2X would produce a significant change in 
receptor activity. 
Among the seven known P2X receptors, the P2X7 receptor in macrophages uniquely 
functions through the release of pro-inflammatory cytokines, like interleukin-1β (IL-
1β).[137]  In this respect, it is interesting to note that bipolar disorder causes atrophy of 
brain tissue, which is proposed to be a result of inflammation [145].  One typical side 
effect of neurodegeneration or neuroinflammation is the cell’s release of ATP, acting as a 
neurotransmitter to signal distress to neighboring cells [146].   This extracellular ATP 
(eATP) is known to have this important signaling role in nervous, vascular, and immune 
systems [147].  By regulating calcium influx, eATP-activated P2X7 mediates the release 
of the IL-1β to respond to inflammation, thereby inducing cell lysis in neurons.  Thus, 
P2X7 is the focus of many current drug discovery efforts as a therapeutic target for 
neurodegenerative diseases [148]. 
Linkage analysis by Nicholas Barden and colleagues suggested a strong association 
of bipolar families with a SNP in the P2RX7 gene which encodes P2X7, resulting in a 
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glutamine to arginine amino acid change in the intracellular carboxy-terminus at position 
460, genetically associating the P2X7 receptor with bipolar disorder [47].  Although this 
claim was refuted by one study [149], a number of reports have confirmed the allelic 
association between SNPs in the P2RX7 gene and bipolar disorder [150-153].  This 
genetic linkage has also been reported between P2RX7 and major depressive disorder 
(MDD) [46, 154]. 
In addition to a genetic connection between P2X7 and bipolar disorder, P2X7 has a 
stronger sensitivity to metal binding than other P2X receptor channels.  Zinc and copper 
have been found to completely inhibit P2X7; these metals only partially inhibit other 
members of the P2X family.  In addition, calcium and magnesium have been shown to 
regulate P2X7 in an allosteric manner by binding to ATP [138].   
The structure of P2X7 has not yet been determined.  However, there is a 45 percent 
sequence identity between P2X7 and P2X4 and, based on structure homology modeling, it 
is likely that the two proteins adopt similar structures [155].  A crystal structure of 
zebrafish P2X4 receptor in the absence of ATP was solved at 3.1 Å resolution (Figure 5-
1; Figure 5-2).  This closed-channel structure, which is the resting state, is a homotrimer 
and forms an ‘hourglass-like’ shape with six transmembrane α-helices, two per monomer 
[156].  A different construct of the zebrafish P2X4 receptor, designed with several 
carboxy-terminal deletions, yielded an ATP-bound crystal structure at 2.8 Å resolution.  
This structure revealed that three ATP molecules bind to this P2X receptor in a 
hydrophilic pocket located between two monomers.  This unique pocket, unlike other 
ATP-binding motifs of proteins, binds ATP in the ‘anti’ conformation where it adopts a   
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Figure 5-1.  Zebrafish P2X4 is shown as a ribbon diagram (blue) to highlight the three 
ATP molecules bound.  The inset displays a closer view of ATP bound to P2X4.  The 
coordinates for this protein structure were retrieved from the PDB, entry 4DW1.  The 
image was rendered in PyMol.
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Figure 5-2. The trimer structure of the zebrafish P2X4 is shown with the monomers in 
green, blue, and purple. An ATP is bound at the interface of two monomers, for a total of 
3 ATP molecules.  The coordinates for this protein structure were retrieved from the PDB 
entry 4DW1, and the image was rendered in PyMol.  
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‘scorpion-like’ shape, with the β- and γ-phosphates folded back toward the adenosine.  
The phosphates are still partially solvent exposed and interact with glycerol, which was 
present as part of the crystallization conditions.  It is proposed that under physiological 
conditions, the glycerol would be replaced with water molecules.  The phosphate oxygens 
interact with four lysines and one arginine [157].  The structure of ATP in this 
extracellular receptor pocket is ideal for the stable formation of Mg·Li binding and water 
coordination. 
Amongst the P2X family, the P2X7 receptor has the longest sequence at 595 amino 
acids, with the longest intracellular C-terminal tail.  The P2X7 receptor channel opens 
with short stimulation by ATP and also forms a larger membrane pore upon prolonged or 
repeated ATP binding.  This pore activates signaling events in inflammation and cell 
death, as well as mitochondrial and cytoskeleton alterations.  Pore formation is also 
reversible [138, 158]. 
In my work, the P2X7 receptor was chosen to test the functional and structural 
consequences of a ternary complex of ATP·Mg·Li because of its genetic association with 
bipolar disorder, sensitivity to metals, and role in inflammation.  However, it remains 
very likely that, if a similar ATP pocket exists in all the subclasses of P2X channels, the 
ATP·Mg·Li ternary complex may modulate to various extents all P2X receptors in a 
similar binding mode.  If this is true, it remains possible that the lithium modulation 
would result in different functional outcomes for each receptor due to variation in P2X 
subclass receptor functions. The P2X receptor, or one of the P2X receptors, may be the 
primary therapeutic target of lithium.  To my knowledge, this research is the first to 
explore the P2X receptor as a therapeutic target of lithium. 
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Experimental Approach 
NMR and fluorescence experiments were planned for testing the ATP-Mg-Li 
ternary complex on both P2X7 in cell membranes and detergent-solubilized P2X7 protein.  
A plan for the expression, purification, and detergent-solubilization of the P2X7 protein 
was developed using methods outlined in the P2X4 crystal structure publication by 
Kawate, et al. as a guide [156].  Heterologous bacterial expression was not a practical 
option because of the post-translational modifications on the human P2X7 protein.  
Instead, a protocol for protein expression in Spodoptera frugiperda 9 (Sf9) cells was 
designed.  Sf9 cells are particularly susceptible to a virus called Autographa california 
Nuclear Polyhedrosis (AcNPV) baculovirus.  As such, baculovirus expression systems 
harness the virus for expressing a recombinant protein of interest in Sf9 cells (Figure 5-
3).  A bacterial plasmid containing the gene of interest is inserted into viral DNA and 
transfects the host insect Sf9 cells.  The Sf9 cells infected with the amplified virus 
produce the protein of interest (BD Biosciences Pharmingen
TM
 BaculoGold Linearized 
Baculovirus DNA).  
 
P2X7 Protein Production 
The P2X7 receptor was designed to have a terminal hexa-histidine-tag, consisting 
of codons for 6 histidines.  At the start of these experiments, there were no commercially 
available P2X7-specific antibodies.  The histidine-tag was both to facilitate detection by 
His-antibody with a secondary antibody reporter on a Western blot and to purify by an 
immobilized metal ion affinity chromatography (IMAC).  A TEV-protease site was 
incorporated for cleavage of the histidine tag during purification.  Three different protein   
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Figure 5-3.  Baculovirus Expression System illustrating the three main steps towards protein expression in Sf9 cells: Co-transfection, 
Amplification, and Expression.
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constructs were designed: full-length P2X7, P2X7 without the two transmembrane 
domains, and P2X7 without the intracellular carboxy-terminus.  The gene for the full-
length construct was cloned into the pFastBac vector (GeneArt®, Thermo Fisher 
Scientific, Inc.). 
The pFastBac plasmid containing the full-length P2RX7 gene was transformed into 
DH5α Escherichia coli (E. coli) cells and the cells were grown in LB containing 
Ampicillin antibiotic.  Plasmid DNA was obtained by mini prep purification (Qiagen) 
and the presence of the gene insert in the plasmid was confirmed by restriction enzyme 
digestion followed by agarose gel analysis and ethidium bromide staining. 
In preparation for transfection into Sf9 cells, the P2RX7 gene was then cloned into the 
pVL1393 vector, which is compatible with the BD Biosciences baculovirus expression 
system, BaculoGold
TM
.  PCR primers were designed to amplify the full-length construct 
gene contained in the pFastBac plasmid.  The pVL1393 vector and PCR product were 
separately digested with restriction enzymes and purified, and then ligated to generate the 
desired recombinant plasmid.  The plasmid was transformed into DH5α cells and purified 
plasmid was obtained as described above, and the sequence of the gene insert was 
confirmed by dideoxy DNA sequencing (Macrogen). 
The pVL1393 plasmid containing the P2RX7 gene of interest and was then used for 
protein expression in the insect cells.  Sf9 cells were cultured to a cell density of 
approximately 0.8 million cells.  Cell density was estimated using a hemacytometer under 
a microscope.  The baculovirus expression protocol was initiated by seeding 
approximately 0.8 million Sf9 cells in mini petri dishes (BD Biosciences BaculoGold
TM
).  
Sf9 cell adhesion to the plate surface was achieved after 10 minutes.  Co-transfection of 
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pVL1393 transfer vector, containing the polyhedron promoter, and the linearized 
baculoviral DNA, lacking a gene adjacent to the polyhedron locus, provided a viable 
recombinant virus by homologous recombination within the host cell.  The ‘P1’ is the 
result of incubating the first round of host cells with the baculovirus for a period of 5 
days at 27
°
C.  However, at that point, the cells were observed to be mostly dead.  Since 
the cells should still be viable at this point, the plasmid was checked on an agarose gel, 
and transfection grade plasmid purification followed. 
Co-transfection of Sf9 cells was repeated using the re-purified pVL1393 plasmid and 
linearized viral DNA.  After 5 days, the supernatant was collected, presumably 
containing the amplified virus.  A dilution assay with Sf9 cells was conducted to 
determine the potency of the virus with increasing concentration of virus in 12 wells of a 
24 well plate.  The first 5 wells contained increasing concentration of an empty vector 
control, and the second row of 5 wells contained increasing concentration of ‘P1’ 
supernatant containing P2RX7-inserted baculovirus.  Two wells had no addition of 
baculoviral DNA to compare the healthy Sf9 cells with the infected cells.  Wells 
containing lower concentrations of baculovirus resulted in a healthy appearance in shape 
but high density, while at higher concentration, the cell morphology changed to 
hexagonal shapes.  To determine whether the P2X7 membrane protein was expressed on 
the Sf9 cell surface, causing this hexagonal morphology, the cells in latter wells were 
collected and a Western blot was run.  The Western blot was inconclusive, as neither the 
Sf9 cells nor the positive control produced a detectable signal.  The Western blots were 
stripped of the antibodies and re-incubated with anti-Histidine antibody followed by the 
secondary antibody conjugated to horseradish peroxidase (HRP), with the same result.  
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SDS-PAGE for the Western blot was repeated with increased cell lysate volume, but 
there was no detectable signal produced by the ECL chemiluminescence system of HRP-
luminol secondary antibody from either the His-tag on the P2X7 or the His-tag on the 
control protein.  Before proceeding further, the ECL chemiluminescene reagents and the 
primary His-antibody were tested using two control proteins containing histidine-tags 
(Figure 5-4).  Three identical Western blots, containing the same two proteins each, 
tested the Histidine-tag primary antibody in the first blot, and the HRP-luminol system in 
the second and third blots.  The controls confirmed that the Western blot detection 
reagents, secondary antibody conjugated with HRP reacting with luminol, function 
sufficiently because the two protein-specific primary antibodies produced a detectable 
signal by this HRP-luminol system.  However, even after a long exposure period, no 
detectable signal was produced by HRP-luminol when the two proteins were incubated 
with the Histidine-tag primary antibody in the first blot.  The Histidine-antibody method 
for detection was reassessed.  Perhaps the His-antibody was a bad batch from the 
company, not nearly as sensitive as it claimed to be, or did not bind tightly enough to the 
secondary antibody.  Regardless, P2X7 protein expression on the Sf9 cells was not 
verifiable by the method engineered for detection. 
It was reasoned that a large yield of protein, purified by IMAC and size exclusion 
chromatography (SEC), would be detectable by SDS-PAGE and NMR.  Co-transfection 
of a new batch of Sf9 cells was initiated to advance baculovirus expression to the stages 
of scale-up without stopping to detect P2X7 by Western blot.  The supernatant containing 
the baculovirus from the first 1 mL of cells, ‘P1’, was used to infect the 5 mL of cells in a   
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Figure 5-4.  Three western blots of two proteins with His-tags, MCM and PCNA.  
Detection by His-tag antibody, MCM antibody, and PCNA Antibody are shown in that 
order (L-R).
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T-25 tissue culture flask, ‘P2’.  Likewise, the P2 supernatant was used to infect 30 mL of 
cells in a T-150 tissue culture flask, ‘P3’.  Finally, the ‘P3’ infected a flask of 120 mL 
cells in suspension.  These cells were collected, centrifuged, separated from the 
supernatant, and lysed.  Purification of the cells continued with sonication, centrifugation, 
solubilization in n-dodecyl-β-o-maltoside (DDM) detergent and protein separation by 
nickel-charged IMAC.  SDS-PAGE of the column eluent and crude cell membrane 
provided no obvious indication of P2X7 presence. 
In one final attempt, fresh Sf9 cells were cultured in a new cell culture facility 
equipped with a new orbital shaker, incubator, and biological safety cabinet.  The sterile 
cell culture room was dedicated to this project in order to determine if there were other 
factors that may be playing a role in protein expression.   After a few days of transition to 
the new environment, Sf9 cells were co-transfected with baculovirus DNA and P2RX7 
transfer vector.  A suspension Sf9 cell culture were infected by the ‘P3’ baculovirus-
containing supernatant.  Following previously mentioned protocol, solubilization of these 
cell membranes, presumed to have expressed recombinant P2X7, were purified over a 
nickel column.  SDS-PAGE revealed no obvious dark band with the protein of interest at 
the molecular weight where we would expect it to appear.  A second gel with the same 
contents as the first was blotted onto nitrocellulose and the Western blot was also 
inconclusive because no bands were visible. 
In the time frame this work was being carried out, the P2X7-antibody was made 
commercially available and was promptly ordered.  However, P2X7 expression in the Sf9 
cells was still not detected by Western blot. 
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The recombinant baculovirus was collected to confirm that the P2RX7 was inserted 
into the linearized baculovirus DNA.  PCR primers were designed to anneal to the 
baculovirus flanking the P2RX7 gene of interest as well as viral DNA.  PCR was 
conducted on the Sf9 baculovirus with P2RX7 insert, and two controls: the baculovirus 
without P2RX7, and the purified plasmid, pVL1393 containing P2RX7 (Figure 5-5).  The 
baculovirus with P2RX7 in Lane 1 of the agarose gel confirmed that the baculovirus 
contains the P2RX7 insert.  The control, baculovirus lacking P2RX7, in lane 2 shows no 
band, as expected, while the purified plasmid, in lane 3, shows a band at approximately 
the same migration point as in lane 1.  This also indicates that the problem with P2X7 
expression may not be at the phase of viral amplification.   
Challenges in the expression of P2X7 prevented moving forward in the research of 
the ternary ATP-Mg-Li complex.  Several potential reasons may be given for expression 
difficulties with this membrane protein.  Human P2X7 may be synthesized by the 
ribosome in Sf9 cells and identified as ‘foreign’, triggering ubiquitinylation and 
degradation by proteases.  It could also emerge from the ribosome misfolded, leading to 
degradation by the host cell.  The aggregation of P2X7 could form insoluble inclusion 
bodies within the cell.  However, if this were the case, there should have been a dark 
band in the cell lysate.  Low protein yield is also a possibility, but it would have to be 
very low to be below the detection of the secondary antibody-HRP, which can detect as 
little as 1 picogram of protein.  A compounding issue may be poor translocation of P2X7 
to the membrane.  If the protein fails to be imbedded into the cell membrane, cytoplasmic 




Figure 5-5.  Agarose gel of digested baculovirus or recombinant plasmid; Lane 1 
contains the digested baculovirus containing the P2XR7 insert.  Lane 2 contains 
baculovirus lacking P2RX7.  Lane 3 shows a digestion of purified recombinant plasmid 
containing the P2RX7 gene. A DNA ladder is used as a marker, labeled ‘M’.
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This chapter summarized the strides made in protein production and purification 
toward reaching the goal of NMR measurements with purified P2X7.  There are several 
ways to move this project forward.  Cellular studies on P2X7 have been published, but 
methods to purify and isolate P2X7 have not yet been reported.  It was reasoned that the 
expression of P2X7 would be similar enough to the published methods of isolation of the 
zebrafish P2X4 to yield enough protein for the purposes of this research.  P2X7 was 
preferred for this Li
+
 research because of its genetic association with bipolar disorder.  In 
hindsight, it would have been better to express P2X4 because it has already been 
expressed and isolated, rather than P2X7.  The expression of membrane proteins is not 
trivial and the differences between members of the P2X family and possibly also between 
species were large enough to prevent expression of P2X7.  The current timeframe for 
developing methods for expressing purified membrane proteins for crystallography can 
be up to 10 years or more.  Since this project is focused on measuring Li
+
 interactions and 
not structure determination, it would be best to proceed with expressing the well 
characterized protein, zebrafish P2X4, by closely following the published protocol from 
the Gouaux lab.  That includes engineering a construct with an octahistidine affinity tag 
and mutating glycosylation sites, as well as using a cobalt IMAC column [156, 157].  
Expression of zebrafish P2X4 would also confirm that the Sf9 baculovirus method works 
in our laboratory setting.  The P2X4 results could be mapped through homology modeling 






A New Molecular Hypothesis for Lithium 
Mechanism of Action 
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There is a wealth of research showing cellular, biological, and clinical effects of 
Li
+
.  A recent review thoroughly summarizes the possible targets of Li
+
 in BD from the 
clinical and cognitive levels down to the cellular levels [159].  The actions of Li
+
 are 
diverse and seemingly unrelated to one another.  Li
+
 appears to be a magical drug, 
enabling patients afflicted with BD to maintain a life without debilitating mood changes.  
It is mysteriously able to balance both the highs of mania and lows of depression. Yet, 
Li
+
’s unknown mechanism makes it difficult to understand biologically, which hinders 
drug discovery efforts from engineering a more effective and ideal BD drug without the 





Evidence for a Bimetallic ATP Complex Model for Lithium’s Mechanism of Action 
 
New physiochemical evidence supports a co-binding, synergistic model of Li
+
 
action rather than one of direct competition with magnesium or other naturally occurring 
metal cation co-factors.  NMR experiments which measure nuclear relaxation and employ 
paramagnetic relaxation enhancement techniques have provided direct physical evidence 
for the formation of a Nucleotide∙Li∙Mg ternary complex where Li
+
 co-localizes with 
Mg
2+
 on the triphosphates of the nucleotide (refer to Chapter 3).  In addition, the 
measured binding affinity of Li
+
 to Nucleotide∙Mg complexes has been found to be in the 
low millimolar range, which is within physiologically relevant concentrations (refer to 
Chapter 3).  This new model is built upon an old hypothesis.  Prior to this recent physical 
evidence, indirect evidence pointed to the possibility of the formation of such a complex.   
In 1976, Dr. Nicholas Birch responded to Dr. Frausto da Silva’s ‘conditional binding’ 
hypothesis , which proposed the idea that Li
+
 acts by challenging common biological 
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cations, with an assertion that one complication to the explanation for their findings had 
not been considered.  This complication was the possibility that Li
+
 forms a complex with 
the ATP, which was only considered by da Silva to be a benign sequestering agent for 
Mg
2+
 [99, 102].  Birch added that he had preliminary unpublished evidence for a ternary 
ADP∙Mg∙Li complex [102].  Further gel filtration equilibrium binding experiments 









 are similar enough to interfere at sites on nucleotides, where Mg
2+
 is 




 on nucleotides was not observed 
[101].  It was proposed that a ternary complex might be possible, but further physical 
evidence was necessary [102].  Now that direct physical evidence exists for 
nucleotide∙Mg∙Li complexes, current biological and pharmacokinetic observations of Li
+
 
action can be reevaluated with this model as the basis for the molecular mechanism of Li
+
 
action. While not directly identifying the target of Li
+
 in its action as a mood disorder 
drug, a better understanding of Li
+
’s molecular mechanism of action and more accurate 
biological hypotheses of the therapeutic action of Li
+
 could lead to a more targeted 
approach to new drug development for BD and give clues to the pathophysiology of BD. 
 
Building a Unified Hypothesis of Lithium action: Biological Targets of Lithium 
through the Prism of the ATP∙Mg∙Li Model 
 
The biological targets of Li
+
 can be reexamined with the new evidence for a 
bimetallic ATP complex to see that Li
+
 may act not only as a simple ion, but as a 
molecular entity (Figure 6-1).  The ternary complex of ATP∙Mg∙Li may help to explain 
how Li
+
 inhibits previously identified enzyme targets of the ion, such as Glycogen   
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Figure 6-1.  Summary of ATP functions that may play a role in the molecular mechanism 
of Li
+
 action as an ATP∙Mg∙Li complex.  ATP acts as a neurotransmitter, danger signal 
during cell death, ligand to receptors and other proteins, and transporter of metals.  ATP 
is metabolized and provides cellular energy for enzymatic reactions.  ATP, adenosine 
triphosphate; GSK3β, glycogen synthase kinase 3β; IMPase, inositol monophosphatase; 
NMDA, N-methyl-D-aspartate receptor; P2X, ligand-gated ion channel purine receptor; 
P2Y, G-protein coupled purine receptor; Rec, receptor; RTK, receptor tyrosine kinase; 
SMIT, sodium myo-inositol transporter; VDAC, voltage-dependent anion channel.  
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Synthase Kinase-3β (GSK-3β) [160], as well as some of the cellular and clinical 
neuroprotective effects observed for Li
+
, as in danger signaling during cell damage and 
cell death and inflammation.  In addition, the physiological roles of ATP also point to 
new biological targets such as purine receptors, neurotransmission, and mitochondria as 
sites for Li
+
 action.  The lens of the ATP∙Mg∙Li complex can focus where to look for Li
+
 
effects across a number of identified and yet to be identified targets, and guide how 





ATP as a Ligand:Receptor Activation Altered by the Mg∙Li Complex with ATP  
The evidence of Mg∙Li co-binding on ATP prompts a reconsideration of how Li
+
 
might have an effect at nucleotide ligand sites.  Purine ligands, ATP or ADP, bind and 
activate cell surface purine receptors, P2, of which there are two subtypes, P2X and P2Y, 
ligand-gated ion channels and G-protein coupled receptors, respectively [161].  The 
seven members of the P2X family each appear to serve various specific purposes, ranging 
from sensory signaling such as pain, taste, and bladder filling, to roles in inflammation, 
and are located on different types of cells.  One of the functions of this receptor family, in 
particular the P2X7 receptor found on immune cells (i.e., mast cells, macrophages, 
microglia, and dendritic cells), is to facilitate inflammatory signaling (see Chapter 5) 
[162].   
Li
+
 may effect changes in these receptors.  In fact, long term damage or negative 
side effects of Li
+
 treatment, such as nephrogenic diabetes insipidus (NDI), may be due to 
Li
+
 affecting purinergic signaling.  Lithium-induced NDI causes ATP-activated purine 
receptors, such as P2Y2, to increase renal prostaglandin (PGE2), which dampens 
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vasopressin, a hormone responsible for retaining water and constricting blood vessels 
[163].  In addition, renal P2X receptors regulate ion and water transport and are vital to 
maintaining physiological electrolyte balance [164].   
Potassium channels are also inhibited by Li
+
 [165].  ATP-sensitive potassium 
channels affect memory and learning in mice and Li
+
 appears to improve memory [165].  
These ATP-sensitive potassium channels in the pre-synaptic neuron also mediate 
neuromuscular transmission and muscle contraction, but are inhibited by LiCl [166]. 
There is an indication that these receptors are sensitive to changes in the chemical 
structure of ATP.  Differential modulation of the P2X7 receptor is seen with ATP analogs 
as the activating ligand.  For example, ATP analogs such as BzATP, 2MeSATP, MeATP, 
ATPγS, and ADP activate or inactivate the receptor to varying degrees [136, 158].  More 
subtly, whole cell patch-clamp electrophysiology recordings reveal modulation of P2X 
receptors to various degrees in response to ATP and ATP analogs depending on the P2X 
subtype [144].  Similarly, Mg∙Li may co-bind to ATP acting as a ligand to a receptor and 
elicit a change in cellular signaling.  
 
ATP as a Danger Signal: Mg∙Li Complexes with ATP May Alter the Signal Mediation 
and Induce Neuroprotection 
Extracellular ATP (eATP) activates cellular receptors to signal that the cell is in 
distress.  Though the details of processes leading to and sustaining the eATP release in 
local high concentrations to convey a danger signal are not well understood, purine 
receptors and adenosine receptors are responsible for responding to this signal, while 
ectonucleotidases, which cause the breakdown of ATP, help to regulate the response with 
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anti-inflammatory signaling [167].  In a mouse model of pulmonary fibrosis, eATP 
activates P2X7 and Pannexin-1 membrane channels, promoting IL-1β maturation, 
pulmonary inflammation and eventually fibrosis, or scarring of lung tissue [168].  
Inflammation is thought to play a role in the pathophysiology of BD, although it is not 
well understood [158].  To that point, in vitro, in vivo, and clinical studies support the 
notion that Li is neuroprotective and prevents cell death.  ATP-induced cell death in rat 
hippocampal brain slices was significantly decreased upon the co-incubation with Li
+
 and 
ATP compared to ATP alone [169].  Intracellular ATP plays a role in danger signaling as 
well.  In particular, apoptosis requires ATP, and ATP depletion creates a bioenergetics 
vacuum leading to the release of cellular contents, inflammation, and necrosis [170, 171].  
One could argue that the concentration and function of ATP, both extracellular and 
intracellular, that is normally involved in danger signaling could again be altered by 
forming a complex with Mg∙Li, which, in turn, could dampen inflammation signaling 
and/or prevent apoptosis, and thereby propagate a neuroprotective effect. 
 
ATP as an Energy Source: Mg·Li Complexes with ATP may Cause Changes in 
Metabolism 
 The cell danger response is intricately balanced to minimize unnecessary damage 
while responding to the immediate problem.  When the response mechanisms are 
functioning abnormally, the cellular components, such as metabolites, that drive the 
danger signal are disrupted.  A series of disorders and chronic illnesses are the result of 
abnormal maintenance of cellular metabolism resulting in aberrant cell danger signaling.  
These include attention deficit hyperactivity disorder (ADHD), BD, schizophrenia, post-
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traumatic stress disorder (PTSD), chronic traumatic encephalopathy (CTE), epilepsy, 
diabetes, and Alzheimer’s and Parkinson’s diseases [167].   
Metabolic energy is largely provided through ATP production by oxidative 
phosphorylation at the inner mitochondrial membrane.   In the mitochondrial matrix, 
citric acid cycle products (reduced nicotinamide-adenine dinucleotide (NADH) and 
Flavin-adenine dinucleotide (FADH2)) become the substrates for oxidation in the electron 
transport chain, resulting in a proton gradient that fuels ATP synthase through 
chemiosmosis to phosphorylate ADP, thus producing ATP [172].  Since ATP provides 
much of the cell’s energy, mitochondria are essential for cell maintenance and health. 
Several diseases have been associated with mitochondrial dysfunction.  Recently, 
mitochondrial dysfunction has been proposed as a cause of BD [173-175].  This 
hypothesis was based on altered cellular energy metabolism measured by functional 
assays and by magnetic resonance spectroscopy studies in patients with BD [176].  In 
addition, neurons from the postmortem brains of BD patients and peripheral cells from 
living BD patients imaged by fluorescence microscopy displayed deviations in size and 
distribution of mitochondria compared to matched controls [177].  Further, 
polymorphisms in the mitochondrial DNA of patients with BD were discovered [174].  A 
specific mutation in mitochondrial DNA, affecting complex I of the electron transport 
chain, also appears to be associated with BD [178].  Additionally, the frontal cortex 
region of the brain in BD patients was analyzed by DNA microarray and revealed the 
differential expression of 831 genes, including several involved in the mitochondrial 
electron transport chain (complexes I, IV, and V).  Interestingly, this report also showed 
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the increase in expression of complex I of the electron transport chain in lithium-treated 
patients compared with non-treated patients [179].  
Mitochondria are not only responsible for energy metabolism through ATP 
production, but also generation of reactive oxygen species, regulating apoptosis, calcium 
signaling, and synaptic plasticity.   Postmortem brains of patients with BD have higher 
nitrosative and oxidative stress, indicative of mitochondrial dysfunction, than controls 
[180].  One report, using quantitative Western blots from postmortem brains, found that 
hexokinase 1 (HK1), which phosphorylates glucose in the first step of glycolysis, binds to 
a voltage-dependent anion channel (VDAC) imbedded in the outer mitochondrial 
membrane, and detaches from the mitochondria in patients with mood disorders.  VDAC 
interacts with part of the inner mitochondrial membrane protein adenine nucleotide 
translocase (ANT), which supports the transport of ADP and ATP [181].   
 The concentration of ATP within the mitochondria, roughly 8 mM, is 




 may be 





 may exert a reparative function on the mitochondrial enzymes 
and processes through the ATP∙Mg∙Li ternary complex.  If validated as drug targets, 






ATP in Enzyme Activity: Mg∙Li Complexes with ATP may Slow or Alter 
Phosphorylation Events. 
In addition to guiding new thinking about Li
+
 targets and mechanism, the Mg∙Li 
bimetallic ATP complex also suggests a mechanistic explanation for how Li
+
 may inhibit 




 is not known as a general 
inhibitor of kinases, but one kinase, Glycogen Synthase Kinase 3β (GSK3β), is a serine-
threonine kinase that is inhibited by Li
+
 at roughly therapeutic concentration (Ki= 2 mM) 
[160, 183-185].  GSK3β is a Mg-dependent enzyme that binds to ATP or ADP ligands.  It 
is a constitutively active enzyme involved in several signaling pathways affecting 
transcription, cell structure, cell cycle, and metabolism [184, 186].  The downstream 
effects of phosphorylation by GSK3β affect many more cellular processes, such as 
synaptic plasticity, apoptosis, and the circadian cycle. Errant GSK3β activity is thought to 
play a role in diabetes, sleep disorders, Alzheimer’s, schizophrenia, depression, and BD, 
among other diseases, which make it an attractive protein for drug inhibitor development 
[187, 188].  
Another important role of GSK3β is in inflammation.  In mice, GSK3 inhibitors 
rescued 70 percent of otherwise lethal doses of a drug that induces inflammation [185].  
Most drugs are reported to bind and compete with ATP in the ATP pocket of GSK3β, 
which has two isoforms,  and β, differing by only one amino acid [188].  Both isoforms 
are inhibited by Li
+
. 
The active site of GSK3β requires two Mg
2+
 ions, and although the catalytic 
mechanism is not well understood, it is hypothesized that Li
+
 inhibits via competition 
specifically with the Mg
2+
 that is not bound to ATP [183, 189, 190].  The ATP-bound 
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structure of GSK3β has not been determined, but the structure of GSK3β bound to a non-
hydrolyzable ATP analog, AMP-PNP, elucidates the active site structure of GSK3β [190] 
(Figure 6-2).  An unexplored possibility of Li
+
 inhibition is the formation of an 
ATP∙Mg∙Li complex that disrupts the activity of GSK3β either directly at the active site 
or allosterically.  Although Li
+
 has a preference for the structure and coordination 
geometry created by ATP∙Mg sites, Li
+
 does not inhibit all kinases or phosphatases at 
therapeutic concentrations, suggesting that while the general model may apply in all 
cases the specific context of individual enzymes will impact the outcome of interaction 
[183].  It is conceivable that a smaller pocket for ATP∙Mg on some kinases may be more 
affected by the presence of and coordination with Li
+
, whereas a larger pocket in other 
kinases may be less affected.  However, further structural elucidation of metal ATP 
complexes with these enzymes will be necessary to understand Li
+
 inhibition more fully. 
Several other enzymes are also directly inhibited by Li
+
, such as Inositol 
monophosphatase (IMPase), Inositol polyphosphate 1-phosphatase, Bisphosphate 
nucleotidease, Fructose 1,6-bisphosphatase, and Phosphoglucomutase (PGM)  [184, 191].  
These are all Mg
2+
-dependent phosphomonoesterases that also provide a potential 
structural pocket at the active site for Li
+
 to form a Mg∙Li complex in a phosphate 
environment. 
IMPase has been the focus of years of BD research because it is inhibited by Li
+
 
at therapeutic concentrations (0.5 mM to 1.5 mM) and plays a role in the central nervous 
system (CNS) [184].  IMPase catalyzes the hydrolysis of myo-inositol monophosphate, 
giving myo-inositol and inorganic phosphate.  Phosphoinositide (PI) signaling facilitates 




Figure 6-2.  The active site of GSK3β (blue) showing AMP-PNP, a non-hydrolyzable 
ATP analog, bound with two Mg
2+
 ions (red).  The structure of the ligand pocket was 
rendered from PDB file 1PYX and image created in PyMol.     
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messengers, like diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3), and 
regulating intracellular calcium.  PI signaling can be initiated by extracellular receptors 
coupled to the G protein, Gq/11.  This G protein then activates Phospholipase C (PLC), 
which, in turn, hydrolyzes the nearby cell membrane component phosphoinositide 4,5-
bisphosphate (PIP2), a phospholipid, initiating PI signaling [184].  In 1989, the ‘inositol 
depletion hypothesis’, a theory for Li
+
’s mechanism of action, was first proposed by 
Berridge et al [192].  It states that Li
+
 inhibition of IMPase interrupts the recycling of IP3 
into inositol, and decreases PIP2 initiation of intracellular signaling [184, 193].  Although 
the mechanism of the Mg-dependent catalysis at the active site of these enzymes is still 
under investigation, biochemical, structural, and molecular dynamics experiments have 
assisted in elucidating its enzymatic action and Li
+
 inhibition. 
The mechanism of Li
+
 inhibition of IMPase and aforementioned phosphatases 
may lie in the common sequence motif and structure at the active site of these 
phosphatases.  The amino acid sequence for the catalytic site of IMPase is conserved with 
other phosphatases, IPPase and FBPase [194].  The amino acid sequence at the catalytic 
site of these enzymes, Asp-Pro-(Ile or Leu)-Asp-(Gly or Ser)-(Thr or Ser), also share a 
similar 3-dimensional core αβαβα sandwich structure among phosphomonoesterases 




 co-bind in a preferred 
manner over two Mg
2+
 ions with ATP (see Chapter 3).  Mg∙Li may be preferred over two 
Mg
2+
 ions in the active site of phosphatases where phosphates are present.  The 
distinctive tetrahedral/octahedral coordination geometry of Mg∙Li may be structurally and 
energetically favored over the native Mg·Mg octahedral/octahedral coordination 




In the case of IMPase, crystallographic and kinetic evidence as well as computer 
modeling have elucidated the metal-assisted catalysis at the active site of IMPase.  
Initially a 2-metal catalysis mechanism was proposed where a higher affinity and a lower 
affinity Mg
2+
 site facilitates the hydrolysis of the substrate, myo-inositol monophosphate 
[197, 198].  This mechanism was revised to 3-metal catalysis after a higher resolution 
crystal structure showed three metals bound at the active site [196, 199].  The 3-metal 
mechanism is currently favored due to its active site structure identity with similar 
enzymes and kinetic and mutagenesis research [199].   
The proposed three-metal mechanism consists of two Mg
2+
 at sites 1 and 3, which 
coordinate the nucleophilic attack of a water hydroxyl on the phosphate of the substrate, 
myo-inositol-1-phosphate (Figure 6-3).  The third Mg
2+
, at site 2, coordinates with the 
substrate hydroxyl to facilitate a hydrogen bond with the phosphate oxygen to stabilize 
the transition state and accelerate the hydrolysis [199].  Indirect evidence shows that the 
Li
+
 binding to  IMPase occurs at the Mg
2+





 at site 2 where Mg
2+
 has a lower binding affinity, and then binds to the 
inorganic phosphate (Pi) leaving group where it forms a tight complex, slowing the 
release of products [199, 200].  Direct evidence of Li
+
 binding to IMPase using 
7
Li NMR 
concludes that there is only one binding site for Li
+
 on IMPase and the data is consistent 
with its location at site 2 [201].  Solid state NMR also confirmed that Li
+
 binds to either 
site 1 or site 2 but not to site 3 [202].  Site 1 is the high affinity Mg
2+
 binding site so it is 
thought that Li
+
 competes with Mg
2+
 at site 2, the lower affinity Mg
2+
 site [199]. 
Computational studies, molecular modeling, and molecular dynamics simulations 




Figure 6-3.  The catalytic site of Inositol monophosphatase (IMPase) is shown 
schematically.  Two Mg
2+
 ions at sites 1 and 3 coordinate with the nucleophilic water 
molecule.  The substrate (inositol monophosphate) 6-OH is hydrogen bonded to a third 
Mg
2+
 ion, which is thought to stabilize the transition state [196, 199]. 
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crystal structure containing the substrate, inositol monophosphate.  Docking of myo-
inositol monophosphate to IMPase indicates how the magnesium triad works together to 
create a hydroxide ion that will hydrolyze the phosphate from myo-inositol 





 at site 2, it has a coordination number of four and is not able to 
coordinate with a water molecule that is key for protonating the leaving groups and 
facilitating enzyme release of products.  So, Li
+
 inhibits IMPase by effectively trapping 
the myo-inositol and inorganic phosphate in the active site [203].  The question of what 
makes Li
+
 attracted to the active site of this enzyme, or favored over magnesium is still 
not known.  It seems counterintuitive that Li
+
 would be preferred over magnesium, and 
yet, at stoichiometric concentrations of Li
+
 and magnesium, Mg∙Li co-binding in 
coordination with phosphates is preferred at specific low affinity magnesium sites.  
However, thinking about this interaction not as a single site for site competition, but 




 to the phosphate ligand site does provide a 
plausible explanation based on the idea that two metal Mg∙Li binding is favored over 
Mg·Mg binding in the enzyme pocket.   
Another protein that Li
+
 inhibits is PGM, which requires Mg
2+
 and also involves 
phosphate binding similar to phosphomonoesterases, but is otherwise dissimilar in 
structure.  PGM is involved in the conversion of glucose-1-phosphate to glucose 6-
phosphate and is indirectly involved in inositol phosphate signaling due to a myo-inositol 
synthesis pathway that uses glucose 6-phosphate as the substrate [204-206].  Adenylate 
cyclase, guanylate cyclase, and G-proteins are also affected by Li
+
 at near physiological 




as well [207-212] creating the possibility that Mg∙Li complexes could form as part of the 
mechanism of inhibition. 
The enzymes presented in the latter half of this chapter do not bind to ATP, but 
interact with phosphates and Mg
2+
.  While ATP is the primary molecule for ternary 
complex formation explored in this chapter, the minimal components of the ternary 
complex are phosphates∙Mg∙Li and it is plausible that Li
+
 is acting as an inhibitor in these 
enzymes through coordination with Mg
2+
 and other phosphate containing ligands, and/or 
sites of amino acid phosphylation at the active sites in the absence of ATP. 
 
Lithium Transport:  ATP as Transport Vehicle for Lithium In and Out of Cells, and 
Around the Body 
 
 The process of exactly how Li
+
 finds its target and is transported throughout the 
body is not fully understood, partly because the therapeutic target(s) of Li
+
 is unknown.  
Lithium carbonate or lithium citrate is administered in the form of an oral tablet and it is 
absorbed in the small intestine for a standard formulation or the small or large intestine 
for a slow-release formulation.  The rate of absorption varies between individuals, but 
nearly 100 percent of a ‘standard’ dose is absorbed.  In approximately 1-2 hours, after a 
standard dose of lithium carbonate, the plasma reaches the peak concentration (3-6 hours 
for a slow-release tablet form).  Experiments measuring gastrointestinal epithelial cells 
upon acute exposure to Li
+
 confirmed cellular influx to be through passive diffusion 





is absorbed by cells through passive diffusion, while approximately 30 percent of cellular 
Li
+
 uptake occurs by the bicarbonate-sensitive pathway, where Li
+
 replaces the hydrogen 
of bicarbonate to ride the anion exchange pathway into red blood cells [213].  Passive 
transport of Li
+
 into the cell occurs through a Na
+






exchanger, or sodium-potassium-two chloride (Na-K-2Cl) co-transporter membrane 




 countertransport mechanism is responsible for the cellular 
efflux of Li
+
, where one intracellular Li
+
 ion is exchanged for an extracellular Na
+
 ion 




 countertransporter, also known as the sodium-sodium exchanger, or 
sodium-lithium exchanger, has a 15- to 18-fold higher affinity for Li
+
 than for Na
+
 [114].  
The physiological concentration gradient of intracellular and extracellular Na
+
 is 
maintained by active transport of Na
+




 pump.  The 
maintenance of the Na
+




 countertransport mechanism to 
pump Li
+
 out of the cell because the intracellular Li
+





 to bind preferentially for cellular export [114, 213].   
Chronic exposure to Li
+
 appears to cause changes in the transport of Li
+
, however.  
After 5 days, the efficiency of Li
+




 countertransport mechanism 
drops by 20-50 percent from non-treated cells.  Two other transport pathways also change 
in the presence of Li
+




 ATPase [213].   
Li
+
 is filtered from the blood through the kidneys for either excretion from the 
body or reabsorption by the body.  Li
+





 antiporter, where it is processed like other electrolytes.  During 
filtration of fluid in the lumen, about 60 percent of Li
+
 is reabsorbed in the proximal 
tubule to circulate in the bloodstream, while about 25 percent is excreted in the urine [74, 
114].  Li
+
 export from renal cells has not been attributed to any one process and has not 
been well characterized.  Active transport of Li
+




 ATPase has not been 
seriously considered as a route for efflux because Li
+
 does not have an affinity for this 
membrane protein [74].   
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Although the mode of Li
+
 efflux from certain cells is unclear, a broadened 
perspective of modes of transport may provide insight into unconventional modes of Li
+
 
transport.  With Li
+
 preferentially forming a complex with ATP∙Mg, ATP may act as a 
shuttle, or carrier, for Li
+
, importing and exporting Li
+
 into and out of cells and around 
the body.   For example, Li
+
 does not directly bind to serum proteins, such as human 
serum albumin (HSA), but ATP has been directly detected by NMR to bind to HSA (see 
Chapter 4).  In fact, up to 10 ATP molecules can bind per HSA protein, with a measured 
KD reported in a wide range from micromolar to millimolar [114, 127], though in the 
presence of competing molecules, like fatty acids, it is unlikely that 10 ATP bind to HSA.  
Still, HSA may be a shuttle for Li
+
 via the ATP∙Mg.  
At the cellular surface and between neighboring cells, hemichannels, embedded in 
the membrane, facilitate the flow of ions and small molecules, such as ATP.  Six protein 
subunits, called connexins, make up a hemichannel [214].  Specifically, connexins assist 
in exporting ATP [215, 216].  When two hemichannels of two neighboring cells come 
together, they form a gap junction channel, enabling cell to cell communication [217].  
The connexin hemichannels on the surface of nodose ganglion sensory neurons, which 
are surrounded by sensory ganglia, or satellite glial cells, were found to participate in 
paracrine signaling by electrophysiology [214].   The details of the ATP involvement in 
paracrine signaling via connexin hemichannels are still being elucidated, but one could 
speculate that during signaling, the addition of Li could alter the speed, localization, or 
export of the ATP∙Mg.  Pannexins are another protein that form a hemichannel and may 
export ATP [218].  However, there is some controversy as to whether Pannexins release 
ATP [214]. 
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ATP release has been observed in P2X7 channels on astrocytes [215].  Prolonged 
activation of the P2X7 purine receptor ion channels by eATP opens up a larger pore to 
allow molecules up to ~900 Da to pass through.  Intracellular ATP can be released from 
the cell through the P2X7 channel upon pore formation [218, 219].   
There are also other transport mechanisms for ATP export from the cell that have 
not received as much attention as those mentioned above.  The calcium homeostasis 
modulator 1 (CALHM1) is able to form a large pore in mouse neurons and is thought to 
be involved in ATP release [218].  Other hypotheses of ATP efflux from the cell are by 
way of the ATP binding cassette transporters, volume sensitive outward rectifying 
(VSOR) chloride channels, and plasmalemmal voltage-dependent anion channels [161, 
219, 220]. 
In addition to transport across the phospholipid bilayer of the plasma membrane, 
certain organelles have mechanisms for transporting ATP.  In peroxisomes, an integral 
membrane protein, called the ATP/ADP antiporter, specifically transfers cytoplasmic 
ATP across the peroxisomal membrane into the lumen of the peroxisome and swaps out 
ADP [221].  ATP is also exported from the mitochondria by the VDAC, mentioned 
earlier [181]. 
Transportation of ATP can also be achieved through exocytosis of vesicles of 
ATP that are stored in neurons and endocrine cells.  ATP exocytosis has been reported in 
astrocytes and microglia as well [215, 222].  In humans, a protein called SLC17 is a type 
of vesicular nucleotide transporter (VNUT) that organizes vesicles of ATP for storage 
and eventually secretion [223]. 
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 channels, and active transport of Li
+
 
by the Na-K pump, a plausible mechanism of Li
+
 transport may be aboard ATP∙Mg in 
typical ATP transporting mechanisms.  This expands the searchable area while offering 
new targets of Li’s therapeutic effect. 
  
ATP as a Neurotransmitter: Mg∙Li Complexes with ATP may Interfere in 
Neurotransmission 
 Considering the therapeutic mechanism of Li
+
 action for the pathophysiology of 
BD, an ATP∙Mg∙Li complex may be most relevant to focus on the central and peripheral 
nervous system, where ATP conveys messages as a neurotransmitter [224].  Synaptic 
release of ATP from the VNUT organized vesicle ranges in ATP concentration from 5 
mM to 100 mM [161].  ATP can be released by itself, or in some instances, as a ‘co-
transmitter’ released along with other neurotransmitters such as glutamate, GABA, 
noradrenaline and neuropeptide Y [161, 218, 225].  As previously mentioned, eATP 
activates P2X and P2Y purine receptors.  In this way, ATP is considered a fast excitatory 
neurotransmitter [218].  One example of ATP acting as a co-transmitter is on the nerves 
surrounding blood vessels causing vasoconstriction [225].  In another, microglia, a 
central nervous system (CNS) sensor of pathology, are responsive to changes in eATP 
released from neurons.  Depending on the concentration of eATP, the dynamic function 
of microglia may change from a ‘sensing’ position with extended processes, to a more 
mobile position, shaped like an amoeba, prepared to migrate to a site of injury and 




 action is by formation of an ATP∙Mg∙Li complex at ATP 
neurotransmitters and modulation of signal transmission.  
 
Summary 
 A few enzymes (e.g., GSK3β and IMPase) and other signaling molecules, such as 
cyclic AMP, GTP-binding proteins, and brain-derived neurotrophic factor (not discussed 
herein), have been studied extensively with regards to BD and have shed light on the 
field, but ultimately have not yet proven to be the therapeutic Li
+
 target for BD.  Rather, 
they seem to be players in a complex, multifaceted neurological disorder.  A unifying 
theme in all of these Li
+
-sensitive enzymes is that phosphates and Mg
2+
 are present and 
may provide a favorable binding location for Li
+
.  One or many of these sites that Li
+
 
binds may prove to be the site of BD pathology or BD therapy, but Li
+
 is a monovalent 
cation, and has a diverse population of molecules with which to interact, both 
nonspecifically and specifically.  Under the umbrella of this ATP∙Mg∙Li model, there is a 
place to fit most of the current hypotheses of Li
+
’s therapeutic mechanism of action.  In 
addition, this model has led to new ways of thinking about how Li
+
 may act (e.g., purine 
receptor modulation).  ATP serves numerous critical functions in the human body from 
signaling to providing energy for enzymatic reactions.  The model of coordinated Li
+
 
binding to ATP∙Mg can serve as a jumping point for a more focused investigation of 
Li
+
’s therapeutic mechanism of action at locations of ATP action hopefully leading to 
answers of some of the bigger questions like, how does Li
+
 stabilize the mood of a 
bipolar patient, and how does Li
+
 provide neuroprotection?  An interesting projection to 
consider with ATP∙Mg∙Li as a model for mechanism of therapeutic action of Li
+
 in BD is 
that rather than a psychological disorder, BD might be a metabolic disorder.  This was 
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first proposed in 1980 by Ehrlich, et al. [213].  Application of this ATP∙Mg∙Li model to 
future Li
+
 research may indeed show that BD is primarily a somatic disorder with 
psychiatric symptoms, but this awaits further evidence.  Nonetheless, the ATP∙Mg∙Li 
model provides a new lens through which to view the age-old question of Li
+
 action and 
can provide some clarity as well as enable broad new insights in the field of Li
+
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